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Summary 
 
Physiological effects of opioids are mediated through binding to specific G protein-
coupled opioid receptors. The µ-opioid receptor (MOPr) is of particular importance for the 
mediation of both the analgesic and the adaptive effects of clinically relevant opioid drugs. After 
opioid binding, the ligand-receptor complex is endocytosed via clathrin coated vesicles. 
Internalized receptors are then either recycled back to the plasma membrane or degraded in the 
lysosome. 
Previous studies have shown that endocytosis of MOPr plays a protective role in the 
development of tolerance to opioid drugs by facilitating receptor reactivation and recycling. It has 
been further demonstrated, that the opioid-mediated activation of phospholipase D2 (PLD2) is a 
prerequisite for MOPr endocytosis and is dependent on small GTPases of ADP-ribosylation 
factor (ARF) family. However, precise identity of ARF protein (ARF1 or ARF6) as well as the 
mechanisms involved in opioid-mediated PLD2 activation by ARF proteins are still not clear. 
By coexpressing the MOPr and different ARF mutants in human embryonic kidney 
(HEK) 293 cells and cultured primary cortical neurons, we have identified the ARF6 protein to be 
involved in the regulation of MOPr endocytosis. This conclusion was based on the two facts: 1) 
overexpression of dominant negative ARF6 mutant blocked receptor internalization after 
treatment with potent endocytotic drug DAMGO and 2) receptor endocytosis was increased in the 
presence of an active, “fast cycling” ARF6 mutant after treatment with morphine, an agonist that 
is unable to induce MOPr endocytosis by itself. Moreover, siRNA-mediated knock down of 
endogenous ARF6 protein expression significantly decreased receptor internalization. Presented 
study also documents that expression of an effector domain mutant of ARF6 which is incapable 
of activating PLD2 (“PLD-defective” mutant) blocked agonist-induced receptor endocytosis 
showing that ARF6 function in MOPr trafficking is PLD2-mediated. Analogously, opioid-
mediated activation of PLD2 is blocked in the presence of dominant negative ARF6 mutants. 
Furthermore, we have also shown that ARF6 protein influences the recycling/reactivation of 
internalized MOPr and thus modulates agonist-induced MOPr desensitization. And finally, we 
demonstrated the importance of GTP hydrolysis of activated ARF6 protein and full GDP/GTP 
cycle for the trafficking of internalized MOPr back to the plasma membrane since locking ARF6 
in its GTP-bound, active state blocked the recycling of the receptor.  
Taken together, these results provide evidence that ARF6 protein regulates MOPr 
trafficking and signaling via PLD2 activation and hence affects the development of opioid 
receptor desensitization and tolerance to opioid drugs.  
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Zusammenfassung 
 
Die physiologischen Effekte von Opioiden werden über die Interaktion mit spezifischen 
G-Protein-gekoppelten Rezeptoren vermittelt. Für die analgetischen und adaptiven Effekte 
klinisch relevanter Opioide ist der µ-Opioidrezeptor (MOPr) von besonderer Bedeutung. Nach 
Opioidbindung wird der Ligand-Rezeptor-Komplex in Clathrin-ummantelten Vesikeln 
endozytiert. Internalisierte Rezeptoren können nun entweder in reaktiviertem Zustand wieder zur 
Plasmamembran zurücktransportiert oder in Lysosomen degradiert werden. 
Frühere Studien zeigten, dass die Endozytose des MOPr aufgrund einer erleichterten 
Reaktivierung/Rezyklisierung von Rezeptoren eine protektive Funktion bei der Entwicklung einer 
Opioidtoleranz besitzt. Es konnte weiterhin gezeigt werden, dass die opioid-vermittelte 
Aktivierung der Phospholipase D2 (PLD2) eine Voraussetzung für die MOPr Endozytose 
darstellt und dass diese Aktivierung über kleine GTPasen aus der Familie der ADP-
Ribosylierungsfaktoren (ARF) vermittelt wird. Allerdings ist die Identität des an der Aktivierung 
der PLD2 beteiligten ARF Proteins (ARF1 oder ARF6) wie auch der Mechanismus der opioid-
vermittelten PLD2 Aktivierung durch ARF-Proteine noch nicht geklärt.  
Durch die Koexpression des MOPr mit verschiedenen ARF Mutanten in humanen 
embryonalen Nierenzellen (HEK293) und primären cortikalen Neuronen konnten wir zeigen, dass 
das ARF6 an der Regulation der MOPr Endozytose beteiligt ist. Diese Schlussfolgerung beruht 
auf zwei Fakten: 1) die Überexpression einer dominant negativen ARF6 Mutante führt zu einer 
vollständigen Blockade der MOPr Internalisierung nach Behandlung mit dem rezeptor-
internalisierenden Agonisten DAMGO; 2) die Rezeptorendozytose nach Behandlung mit dem 
nicht rezeptor-internalisierenden Agonisten Morphin war in Gegenwart einer aktiven "fast 
cycling" ARF6 Mutante deutlich erhöht. Zusätzlich führte die Verminderung der endogenen 
ARF6 Expression mittels siRNA zu einer signifikanten Abnahme der Rezeptorinternalisierung. 
Die vorliegende Studie zeigt auch, dass die Expression einer ARF6-Mutante, die keine PLD2 
Aktivierung auslösen kann ("PLD2-defekte" ARF Mutante), zu einer Blockade der agonisten-
induzierten Rezeptorendozytose führt. Dies Ergebnis zeigt, dass die Funktion von ARF6 bei der 
Regulation des intrazellulären MOPr Transportes über die Aktivierung der PLD2 vermittelt wird. 
Analog dazu ist die opioid-vermittelte Aktivierung der PLD2 in Gegenwart einer dominant 
negativen ARF6 Mutante blockiert. Darüberhinaus konnten wir zeigen, dass das ARF6 Protein 
die Rezyklisierung/Reaktivierung von internalisierten MOPr beeinflusst und somit die die 
agonisten-induzierte Desensitisierung moduliert. Abschliessend konnte gezeigt werden, dass die 
GTP-Hydrolyse des aktivierten ARF6 und somit ein kompletter GDP/GTP Zyklus für den 
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Rücktransport des internalisierten MOPr an die Plasmammembran notwendig ist. So führt die 
Expression einer GTPase defizienten ARF6 Mutante, die das ARF6 in der GTP-gebundenen 
aktiven Form hält, zu einem Verlust der MOPr Rezyklisierung.  
Zusammenfassend zeigen die vorliegenden Ergebnisse, dass das ARF6 Protein den 
intrazellulären Transport und die Signaltransduktion des MOPr über die Aktivierung der PLD2 
reguliert und dadurch die Entwicklung einer Opioidrezeptor Desensitisierung und Opioidtoleranz 
beeinflusst.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Modulation of µ-opioid receptor signal transduction and endocytosis by ADP-ribosylation factor proteins 
- Introduction - 
 
- 4 - 
 
 
 
1. Introduction 
 
 
Opium, a preparation of the opium poppy papaver somniferum, has been used for 
thousands of years to relieve pain and to alter mood. The oldest records about the use of opium 
poppy as a “joy plant” are from the ancient Sumerian civilization that existed four thousand years 
B.C.. Later, the use of opium poppy juice has spread and by the 10
th
 and 11
th
 centuries A.D., the 
opium trade was firmly established in Europe (Berridge and Edwards, 1981).       
 In 1806, morphine (named after Morpheus, the Greek god of dreams) was isolated by 
Friedrich Sertürner and later shown to be almost entirely responsible for the analgesic activity of 
crude opium. Over the next decades, several other alkaloids, such as codeine and papaverine, 
were isolated. Heroin, the first semi-synthetic opioid, was produced in 1874 and while it was first 
used in medicine, later it became a popular opioid drug of abuse.  
 To date, opioids such as morphine are still the best analgesic choice in the treatment of 
chronic and serious pain, such as cancer pain. However, it is now well recognized that their 
extensive and long-term use leads to development of physiological tolerance and dependence (see 
Chapter 1.3.4.), adaptive changes in the nervous system that greatly limit the therapeutic use of 
opioid drugs (for review see Taylor and Fleming, 2001). In addition, opioid drug abuse is still a 
great problem nowadays. Due to these reasons, one of the major goals in opioid research is to 
develop drugs or administration strategies that result in effective analgesia without the 
detrimental adaptive responses. 
 
1.1. Opioids  
 
Extensive research has resulted in many distinct opioids being isolated. Some of them 
were discovered endogenously and some were synthetically derived. Many of these compounds 
are still used medically or abused illegally and therefore we could say that opioids today play 
both beneficial and deleterious role in society.    
The term opioid applies to the chemical substances that have a morphine-like action in 
the body, including analgesia, sedation, euphoria as well as respiratory depression and 
antidiarrhea. There are several classes of opioids: 
 Natural opiates, alkaloids contained in the resin of the opium poppy including 
morphine and codeine; 
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 Semi-synthetic opiates, created from the natural opioids, such as hydromorphone, 
hydrocodone, oxycodone, oxymorphone, buprenorphine, diacetylmorphine (heroin) 
etc. 
 Fully synthetic opioids, such as fentanyl, pethidine, methadone, tramadol and 
propoxyphene; 
 Endogenous opioid peptides, produced naturally in the body, such as β-endorphin, 
enkephalins, dynorphins and endomorphins. 
Although the term opiate is often used as a synonym for opioid, it is more properly limited to the 
natural opium alkaloids and the semi-synthetics derived from them. 
 
1.2. Opioid receptors 
1.2.1. Structure of opioid receptors 
 
Opioids mediate their physiological effects by binding to specific opioid receptors in the 
central nervous system and in other tissues, mainly in the gastrointestinal tract. In 1973, three 
groups of researchers independently identified stereospecific binding sites for opioids in 
mammalian nervous system (Pert and Snyder, 1973; Simon et al., 1973; Terenius, 1973). Later, 
the begin of the 20
th
 century was marked by cloning of genes encoding three well defined or 
“classical” types of the opioid receptors: µ (mu), δ (delta) and κ (kappa) opioid receptor (Kieffer 
et al., 1992; Evans et al., 1992; Chen et al., 1993a; Minami et al., 1993; Fukuda et al., 1993; Li et 
al., 1993; Meng et al., 1993; Yasuda et al., 1993; Wang et al., 1993). Sequence analysis revealed 
that these receptors belong to the superfamily of G protein-coupled receptors (GPCRs) and the 
subfamily of rhodopsin receptors. As shown in Figure 1.1., the µ-, δ- and κ-opioid receptors have 
seven transmembrane domains of 20-25 hydrophobic residues that form α-helices, three intra- and 
three extracellular loops, extracellular N-terminus and intracellular C-terminal tail. These 
receptors are about 60% identical to each other, with the greatest homology found in the 
transmembrane domains (73-76%) and intracellular loops (86-100%). The lowest homology in 
amino acid sequence is found in the N-terminus (9-10%), extracellular loops (14-72%) and the C-
terminus (14-20%) (Chen et al., 1993b; Law et al., 2000). 
Numerous pharmacological studies have suggested subtypes of the µ-opioid receptor 
(MOR1) and studies have raised the possibility that some of these might reflect splice variants of 
the MOR1 gene (Wolozin and Pasternak, 1981; Pasternak, 1993; Pasternak and Standifer, 1995). 
Two MOR1 variants, MOR1A and MOR1B, were identified shortly after the initial cloning of 
MOR1 (Bare et al., 1994; Zimprich et al., 1995). Thereafter, additional MOR1 splice variants 
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were continually identified and characterized (Pan et al., 1999, 2000, 2005; Pasternak et al., 
2004). However, more recent nomenclature for the µ-opioid receptor is MOPr and therefore this 
abbreviation has been used in this work. 
 
                        
Figure 1.1. Structure of opioid receptors (modified from LaForge et al., 2000). Opioid 
receptors have a central common core composed of seven transmembrane helices connected by 
three intra- and three extracellular loops. The differences in N-terminal and C-terminal length for 
each receptor type are shown. 
 
                     
1.2.2. Effector mechanisms of opioid receptors and opioid receptor-evoked cellular 
responses 
 
As mentioned above, opioid receptors belong to the family of GPCRs. They are 
prototypical “Gi/o coupled” receptors because receptor signaling can be blocked by pertussis toxin 
(PTX), a bacterial toxin produced by Bordetella pertussis that is commonly used as a 
pharmacological tool to inactivate the α-subunit of Gi/o proteins.  
The binding of agonist to extracellular domains of opioid receptor induces a 
conformational change that promotes the exchange of guanosine diphosphate (GDP) for 
guanosine triphosphate (GTP) on the α-subunit of Gi/o protein coupled to the receptor. This allows 
the dissociation of the G protein into Gα subunit and Gβγ dimer which carry the signals to their 
effectors, namely enzymes and/or ion channels. Generally, through coupling to Gi/o family of 
heterotrimeric G proteins, opioid receptors activate a class of inwardly rectifying potassium 
channels and inhibit certain voltage-sensitive calcium channels. Moreover, acute stimulation of 
opioid receptors leads to inhibition of the adenylate cyclase (AC) and decrease in production of 
Modulation of µ-opioid receptor signal transduction and endocytosis by ADP-ribosylation factor proteins 
- Introduction - 
 
- 7 - 
 
cAMP (cyclic adenosine monophosphate) and can activate a number of kinase-mediated signaling 
cascades, thereby having additional effects on cytoplasmic signaling events and controlling neural 
gene expression (see Law et al., 2000 and Williams et al., 2001 for reviews). The summary of 
opioid receptor-evoked cellular responses is shown in Figure 1.2. 
 
 
Figure 1.2. Main opioid receptor-evoked cellular responses. Binding of µ-opioid receptor 
agonists (e.g. morphine) results in the following Gi/o protein mediated intracellular effects: 
inhibition of the adenylate cyclase (AC), inhibition of voltage-dependent Ca
2+
 channels, 
activation of inwardly rectifying K
+ 
channels, activation of phospholipase C and activation of 
MAP kinase. NT stands for neurotransmitter. 
 
 
The anatomical localization of the µ-opioid receptors in the brain is consistent with 
known pathways of nociceptive signaling. They are expressed on peripheral nociceptors after 
inflammation, on spinal cord dorsal horn neurons and on the neurons in the various regions of the 
brain involved in pain perception and processing. Interruption of nociceptive signaling is the basis 
of analgesic effects of opioids. However, since the receptors are also expressed in the periphery 
(including gastrointestinal tract and skin) and not only in pain processing brain regions, activation 
of opioid receptors triggers not only analgesia but also numerous unwanted effects such as 
sedation, nausea and vomiting, constipation and respiratory depression, confusion, hallucinations, 
nightmares, dizziness, dysphoria, hyperalgesia, etc. 
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On the cellular level, a decrease of the calcium ion (Ca
2+
) influx induced by activation of 
µ-opioid receptors on presynaptic neurons leads to a reduction of a neurotransmitter release into 
the synaptic gap. On the postsynaptic side, activation of µ-opioid receptors enhances the 
potassium ion (K
+
) efflux resulting in a hyperpolarization of postsynaptic neurons. Thus, 
activation of pre and postsynaptic µ-opioid receptors on spinal cord dorsal horn neurons leads to a 
decrease of synaptic nociceptive transmission. In such a way, opioids exhibit their analgesic 
effects. In contrast to the immediate effects on pain transmission, alterations in the cAMP levels 
are associated with cellular changes that lead to the development of tolerance and physical 
dependence to opioids.  
Although acute opioid treatment induces inhibition of AC and cAMP reduction, it has 
been shown that chronic opioid treatment followed by opioid withdrawal leads to enhanced AC 
activity and cAMP accumulation, a phenomenon termed AC superactivation. This has been 
considered as a cellular hallmark of opioid withdrawal (Bohn et al., 2000; Fin and Whistler, 
2001). However, mechanisms that are responsible for AC superactivation are still controversially 
discussed (for review see Liu and Anand, 2001).  
 
1.2.3. Regulation of µ-opioid receptor activity 
 
 Like most GPCRs, the µ-opioid receptor can be regulated by multiple mechanisms 
including receptor desensitization, internalization (endocytosis), resensitization and 
downregulation. 
 MOPr-mediated signal transduction is usually rapidly attenuated by process of receptor 
desensitization. Namely, as shown in Figure 1.3., following agonist treatment, the receptor 
becomes phosphorylated by G protein-coupled receptor kinases (GRKs) (Kovoor et al., 1997; Pak 
et al., 1997; Wolf et al., 1999; Deng et al., 2000; Wang, 2000; Law et al., 2000, Schulz et al., 
2004) or second messenger-regulated protein kinases, such as Ca
2+
/calmodulin-dependent kinase 
II (Mestek et al., 1995; Koch et al., 1997, 2000; Brüggemann et al., 2000) and mitogen activated 
protein (MAP) kinase (Polakiewicz et al., 1998; Schulz and Höllt, 1998; Schmidt et al., 2000). 
Phosphorylated receptors then associate with β-arrestins and this leads to uncoupling of receptors 
from heterotrimeric G proteins disrupting their signaling and causing receptor desensitization. In 
addition, β-arrestins bind to clathrin heavy chain and the β2-adaptin subunit of heterotrimeric AP-
2 adaptor complex and therefore physically link and target receptors to clathrin-coated pits and 
endocytic membranes (for review see Claing et al., 2002). Once the plasma membrane is 
invaginated, the GTPase dynamin wraps around and constricts the necks upon GTP hydrolysis 
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leading to vesiculation and internalization (endocytosis) of the receptor. Internalized vesicles 
soon shed their clathrin coats and fuse with early endosomes. The ligands and receptors are 
separated in the acidified perinuclear compartment, β-arrestins dissociate and the receptors are 
either dephosphorylated by phosphatases and recycled back to the plasma membrane or are 
targeted to lysosomal degradation. This process is called „post-endocytic sorting‟ (von Zastrow et 
al., 2003). Dephosphorylation and subsequent recycling of receptors contributes to a reversal of 
the desensitization state (resensitization), which is required for full recovery of cellular signaling 
potential following agonist removal. It is now well accepted that different opioid agonists induce 
receptor phosphorylation, desensitization, and internalization to a different extent. However, the 
molecular mechanisms underlying these differences remain unsolved. Moreover, it is known that 
after acute stimulation of MOPr with agonists that induce receptor endocytosis, most of the 
receptor is recycled back to the plasma membrane and a significant degradation of receptor is not 
detected.  
 
    
clathrin
sorting compartment
dephosphorylation
Agonist binding
recycling
endosome
lysosomeearly endosome
H+
ß-arrestin
G-protein
GRK/
CamK II
phosphorylation
phosphorylation
ß-arrestin binding
and uncoupling
 
 
Figure 1.3. Agonist-induced endocytosis and recycling of the µ-opioid receptor. After agonist 
treatment, receptor is phosphorylated by kinases and uncoupled from G-proteins by β-arrestin 
binding. β-arrestin also promotes receptor internalization by clathrin recruitment. Following 
internalization, receptors are sorted in endosome and either dephosphorylated and recycled back 
to the plasma membrane in reactivated state or targeted to lysosome for degradation. GRK= G 
protein coupled receptor kinase; CamKII= Ca
2+
 - calmodulin dependent protein kinase II. 
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 Receptor downregulation refers to a decrease in the total number of receptors present in 
cells or tissues, which is typically induced over a period of hours to days after prolonged or 
repeated exposure to opioid agonist (Tsao and von Zastrow, 2000). It is a consequence of 
proteolytic or lysosomal degradation of the internalized receptors and therefore the recovery from 
downregulation is dependent on new protein synthesis.  
 
1.2.4. Opioid tolerance and dependence 
 
Opioid tolerance, as well as physical or physiological dependence to opioids, develops 
after prolonged use of opioid drugs, over hours/days to weeks. Tolerance is a decrease in 
responsiveness manifested as a loss of response to a given dose of an agonist, or the requirement 
for an increased dose to achieve the original effect. Dependence is a different phenomenon, much 
more difficult to define and measure, which involves two separate components, namely physical 
and psychological dependence. Physical dependence is associated with a physiological 
withdrawal syndrome (or abstinence syndrome), manifesting as extreme restlessness and distress. 
Re-administartion of morphine rapidly abolishes the abstinence syndrome. Drug users who are no 
longer physically dependent can still show psychological dependence manifested by a strong 
craving for drugs and relapse. 
It is increasingly evident that opioid-induced tolerance and dependence occur as adaptive 
changes at multi-levels in the nerve cell, beginning with regulation of opioid receptors themselves 
and extending to a complex network of direct and indirect modifications of “downstream” 
signaling machinery. It is known that traditional mechanisms like receptor phosphorylation, G 
protein uncoupling, receptor downregulation, desensitization, AC superactivation, the amount of 
effector proteins etc. are implicated in the development of opioid tolerance and dependence, but 
precise mechanisms involved in this complex phenomena still remain elusive.  
To address this complex issue, cellular models of tolerance have been developed (Taylor 
and Fleming, 2001; Kieffer and Evans, 2002; von Zastrow et al., 2003; von Zastrow 2004) and 
different opinions were created. According to prevailing hypothesis, it was assumed that receptor 
endocytosis leads to a decrease in receptor signaling by receptor desensitization after prolonged 
agonist treatment. Moreover, receptor internalization and degradation after agonist treatment 
results in fewer available receptors at the cell surface and together these events would favor 
development of cellular tolerance to opioids. However, recent studies
 
have demonstrated that 
endocytosed µ-opioid receptors
 
are predominantly and rapidly recycled to the cell surface in
 
a 
reactivated state (Ferguson et al., 1998; Koch et al., 1998,
 
2001; El Kouhen et al., 1999;Law et 
Modulation of µ-opioid receptor signal transduction and endocytosis by ADP-ribosylation factor proteins 
- Introduction - 
 
- 11 - 
 
al., 2000). These findings
 
led to a revision of the prevailing hypothesis and suggest that
 
µ-opioid 
receptor endocytosis is an important mechanism
 
in ensuring that desensitized and internalized 
receptors are
 
rapidly recycled to the cell surface in an active form, maintaining
 
receptor signaling 
and reducing receptor desensitization and
 
tolerance development (Koch et al., 1998, 2001; Finn 
and Whistler,
 
2001). In this revised model, noninternalizing agonists such
 
as morphine cause an 
accumulation of desensitized receptors
 
in the plasma membrane, resulting in greater opioid 
tolerance
 
(Koch et al., 2001, 2004; Schulz et al., 2004).
 
 
 
1.3. Regulation of MOPr endocytosis 
 
Receptor endocytosis has been in the center of opioid research for a long time since it is 
an important step in signaling regulation of many GPCR. It also has been implicated in 
physiological adaptations to opioid agonist treatment (von Zastrow, 2001; von Zastrow et al., 
2003). Moreover, recently it has been shown that rapid recycling of internalized µ-opioid 
receptors in a reactivated form back to the plasma membrane counteracts development of opioid 
tolerance as mentioned above (Koch et al., 2005). Thus, regulators of receptor endocytosis and 
trafficking might play a critical role in the development of opioid tolerance and dependence, 
together with other mechanisms involved in these complex phenomena. Good candidate 
molecules for these regulators might be proteins interacting with MOPr. 
 
1.3.1. Phospholipase D2 (PLD2) 
 
Investigation of molecules involved in µ-opioid receptor endocytosis and recycling 
identified phospholipase D2 (PLD2) as a novel µ-opioid receptor interacting protein (Koch et al., 
2003). Furthermore, it has been shown that PLD2 is activated by binding of receptor internalizing 
agonists to MOPr and that this activation is dependent on ADP-ribosylation factor (ARF) protein 
and essential for receptor endocytosis (Koch et al., 2003, 2006). However, the mechanisms 
involved in PLD2 activation and regulation of receptor endocytosis are still not clear. 
PLD2 is a membrane associated phospholipid-specific phosphodiesterase that catalyses 
hydrolysis of phosphatidylcholine (PC), a major phospholipid in the cell membrane, to 
membrane-bound phosphatidic acid (PA) and soluble choline (for review see Liscovitch et al., 
2000). PA has been implicated to have many different functions in signal transduction, vesicle 
formation, and cytoskeleton dynamics (Liscovitch and Cantley, 1995; Liscovitch et al., 1999). 
Beside simple hydrolysis, PLD2 can catalyze transphosphatidylation reactions using short-chain 
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primary alcohols, e.g. ethanol, as phosphatidyl-group acceptors. Resulting phosphatidylalcohols 
are not normally found in biological membranes and their formation can serve as a convenient 
and sensitive marker for PLD activation in cultured cells (PLD assay). 
Up to now, two mammalian PLDs, PLD1 and PLD2, have been cloned (the structures of 
the enzymes are shown in Figure 1.4.).  Subcellular fractionation studies have demonstrated the 
presence of PLD1 in intracellular membranes like endoplasmatic reticulum, Golgi and vesicular 
compartments, whereas PLD2 has been shown to be largely associated with plasma membrane 
(Liscovitch et al., 1999). Both PLD enzymes require phosphatidylinositol-4,5-biphosphate (PIP2) 
as a cofactor necessary for enzyme activity and proper membrane targeting. Other main 
regulators of PLD activity are protein kinase C (PKC) and small GTPases of the ARF and Rho 
families (Liscovitch et al., 2000; Exton, 2002; Hiroyama and Exton, 2005).  
 
 
                
 
 
 
 
Figure 1.4. Domain structure of PLD isoforms. Both enzymes have four conserved sequences 
(I-IV), two of which contain catalytic HKD motif (where H is histidine, K is lysine and D is 
aspartate) which is conserved in numerous enzymes of phospholipid metabolism. Pleckstrin 
homology (PH) and phox homology (PX) domains present in tandem at N-terminus are 
implicated in phospholipid and protein binding (Frohman et al., 1999; Exton, 2002). N-terminally 
to domain III is a well conserved basic sequence that binds PIP2. PLD1 is distinguished from 
PLD2 by a loop region that seem to contribute to the regulation of PLD1 activity. 
 
Beside its important role in regulation of various cellular processes such as exocytosis, 
secretion and cytoskeletal reorganization, it has been shown that PLD2 can be regulated by a 
number of GPCRs including VPAC 1 and 2 receptors and PAC1 receptor (McCulloch et al., 
2001), metabotropic glutamate receptors (Shinomura et al., 2000; Kanumilli et al., 2002; 
Bhattacharya et al., 2004), m1-m4 muscarinic receptors (Sandmann et al., 1991; Mitchell et al., 
2003), the endothelin receptor (Ambar and Sokolovsky, 1993), the 2-adrenergic receptor 
(MacNulty et al., 1992), the D2 dopamine receptor (Senogles, 2000), the somatostatin sstr2 
receptor (Cheng et al., 2005), the 5HT2A-receptor (Johnson et al., 2006), the cannabinoid 
receptor isoform 1 (Koch et al., 2006) and the µ- and -opioid receptor (Koch et al., 2003, 2006).  
Recent studies implicated an involvement of receptor-mediated PLD2 activation in the regulation 
of receptor endocytosis (Bhattacharya et al., 2004; Koch et al., 2006; Shen et al., 2001; Du et al., 
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2004). In addition, our group has previously shown that activation of PLD2 is a key step during 
the induction of agonist-mediated endocytosis and recycling of the MOPr affecting the 
development of opioid tolerance (Koch et al., 2003, 2004). However, the mechanism by which 
opioid receptors stimulate PLD2 activity has not been well established.  
What is the role of PLD2 in endocytosis of GPCRs? Most cellular responses following 
enzyme activation are mediated by the PC hydrolysis product, PA. Besides being a 2
nd
 messenger, 
PA can be further metabolized to other bioactive lipids, such as lysophosphatidic acid (LPA) and 
diacylglycerol (DAG). It can alter physical and chemical properties of the plasma membrane (pH, 
charge, etc.) to assist formation of membrane curvature and to help formation of vesicles together 
with other acidic phospholipids. In addition, PA can affect both cellular localization and activity 
of various proteins (Jenkins and Frohman, 2005), like phosphatidylinositol-4-phosphate-5-kinase 
(PIP5K), an enzyme that synthesizes PIP2 which is a PLD cofactor.  Moreover, PIP2 regulates the 
clathrin-dependent endocytosis by membrane recruitment of dynamin, GTPase responsible for 
fission of budding vesicles from membrane and components of the AP-2 adaptor complex. 
Therefore, opioid-activated PLD2 migth have a multiple roles in MOPr endocytosis and 
signaling. 
 
1.3.2. ADP-ribosylation factor (ARF) proteins 
 
Previous work demonstrated that PLD2 is predominantly activated by ARFs and not by 
PKC (Exton, 2002; Hiroyama and Exton, 2005; Koch et al., 2003). The ARF proteins belong to 
the Ras superfamily of small GTPases (for review see D’Souza-Schorey and Chavrier, 2006). 
These low molecular mass proteins (~20 kDa) are myristoylated at the second glycine (Gly) 
residue of the N-terminus, and this lipid modification seems to be important for the tethering of 
ARF proteins to membranes (Amor et al., 1994). Like other GTP-binding proteins, ARFs cycle 
between their active (GTP-bound) and inactive (GDP-bound) conformations. Hydrolysis of 
bound GTP is mediated by GTPase-activating proteins (GAPs), whereas the exchange of GDP for 
GTP is mediated by guanine nucleotide exchange factors (GEFs). In the recent years, an 
increasing number of these ARF regulators has been identified (Donaldson and Jackson, 2000).  
Based on amino acid sequence identity, the six mammalian ARF proteins are categorized 
into three classes. Class I ARF proteins (ARF1, ARF2, and ARF3) regulate trafficking in the 
secretory pathway and in endosomes (Bonifacino and Glick, 2004). However, very little is known 
about the functions of class II ARFs 4 and 5. ARF6, which is the sole member of class III ARF 
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proteins, is thought to regulate actin cytoskeleton arrangement and endosomal trafficking at the 
cell surface (D’Souza-Schorey et al., 1995; Peters et al., 1995). 
From six members of the ARF family of small GTPases, ARF1 and ARF6 are the best 
described. Both molecules are important components of the molecular machinery that regulates 
membrane trafficking along endocytic and biosynthetic pathways and are involved in activation 
of lipid-modifying enzymes like PLD and PIP5K. Since their GTP-bound, active conformations 
are very similar (Pasqualato et al., 2001), it seems that in vivo the specificity of ARF1 or ARF6 
for their downstream effectors is regulated by their distinct localizations in the cell. ARF1 is 
localized mainly to the Golgi complex where it regulates the assembly of different types of 'coat' 
complexes onto budding vesicles, whereas ARF6 is associated to the plasma membrane and 
involved in regulation of plasma membrane/endosome trafficking as well as actin cytoskeleton 
rearrangements as mentioned above.  
However, it has been shown that ARF1 can be also recruited to the plasma membrane 
upon activation of some GPCRs (Mitchell et al., 2003). Moreover, both ARF1 and ARF6 proteins 
have been reported to interact with different GPCRs and to be involved in regulation of their 
trafficking and signaling events (Mitchell et al., 2003; Mitchell et al., 1998; Robertson et al., 
2003; Johnson et al., 2006). The authors proposed a conserved NPxxY motif (where N is 
asparagine, P is proline, x is any amino acid and Y is tyrosine) found in C-terminal part of most 
of GPCRs as a possible ARF binding site. The receptors that do not have an NPxxY motif, such 
as metabotropic glutamate receptors, have been demonstrated to activate PLD2 in an ARF-
independent but PKC-dependent way (Bhattacharya et al., 2004). Since the NPxxY motif is 
present also in MOPr, this data suggest that a direct binding of ARF protein(s) can be involved in 
receptor mediated activation of PLD2. However, previous studies revealed that for a 
coimmunoprecipitation of MOPr and ARF protein the presence of PLD2 seemed to be important 
(Koch et al., 2003). Thus, it is reasonable to assume that ARF binds directly to PLD2 rather than 
to MOPr, but it can not be excluded that an interaction with PLD2 induces a conformational 
change of receptor which is necessary to facilitate ARF binding to MOPr. Having this in mind, it 
can be suggested that there is some kind of functional “ternary complex” formed between MOPr, 
PLD2 and ARF protein upon opioid treatment and formation of this complex seems to be 
important for opioid-mediated PLD2 activation and MOPr endocytosis. However, the identity of 
ARF protein (ARF1 or ARF6) as well as the precise interactions in this hypothetical “ternary 
complex” remain to be investigated. 
To study cellular effects of ARF proteins, different mutants are described. As mentioned 
above, ARFs cycle between their inactive, GDP-bound state and their active, GTP-bound state. 
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Therefore the function of these proteins is largely investigated by using dominant negative and 
constitutively active mutants which are thought to be “locked” in GDP- and GTP-bound states, 
respectively. However, some recent studies have shown that in the case of ARF6 these “classical” 
mutants, namely dominant negative ARF6/T27N and constitutively active ARF6/Q67L, show 
some artifacts in vivo (Macia et al., 2004; Santy, 2002; Klein et al., 2006). Namely, it was 
demonstrated that ARF6/T27N mutant has a high tendency to lose its nucleotide and to denature 
in vitro (Macia et al., 2004) and thus, is no longer located in the plasma membrane where ARF6 
normally resides. To overcome these problems, another dominant negative ARF6 mutant, 
ARF6/T44N was generated, which has a 30-fold decreased affinity for GTP in comparison to the 
wild type protein and, importantly, is properly located in the plasma membrane in vivo (Macia et 
al., 2004). This mutant has been suggested to be a better choice for investigation of blocking 
ARF6 function in vivo. On the other hand, regarding active ARF6 mutants, the “fast cycling” 
ARF6/T157N mutant was found to induce phenotypes that have been previously attributed to 
ARF6 activation without the toxic effects demonstrated after “classical” constitutively active 
ARF6/Q67L mutant expression (Santy, 2002; Klein et al., 2006). This mutant “cycles” i.e. binds 
GTP and releases GDP more quickly than the wild type protein and therefore has an enhanced 
activity in vivo. Moreover, unlike ARF6/Q67L mutant that is “locked” in its GTP-bound form, 
“fast cycling” ARF6/T157N retains a full cycle of GTP binding, hydrolysis and release which is 
necessary for proper function of ARF6 and therefore is suggested to represent better the ARF6 
active form in vivo (Santy, 2002; Klein et al., 2006). 
 
 
1.4. The aim of the present research project 
 
 
Agonist-induced endocytosis is an important regulatory and signaling event for G 
protein-coupled receptors (for review see von Zastrow, 2001). For the mu-opioid receptor, the 
investigation of molecular mechanisms regulating this process is of clinical importance because 
MOPr endocytosis counteracts the development of tolerance to opioid drugs by facilitating the 
reactivation of desensitized receptors (Koch et al., 2005).  
In search of molecular players involved in MOPr endocytosis, our group has recently 
identified phospholipase D2 as a MOPr interacting protein (Koch et al., 2003). This ubiquitously 
expressed and plasma membrane located enzyme was previously reported to be activated by a 
great variety of hormones, neurotransmitters, growth factors, cytokines and stimulation of various 
GPCRs (reviewed in Liscovitch et al., 2000). We have further demonstrated that the opioid-
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mediated activation of PLD2 is ARF-dependent and is a prerequisite for MOPr endocytosis. 
However, it is still not known which ARF protein (ARF1 or ARF6) is involved in opioid-
mediated PLD2 activation and what are the mechanisms of ARF function in MOPr trafficking 
and signaling. 
ARF1 and ARF6 are the best described members of ARF family of small GTPases. Both 
molecules have been reported to interact with different GPCRs and to be involved in regulation of 
their trafficking and signaling as mentioned above. Although very similar in structure, these 
proteins differ in their effectors and downstream signaling pathways. Thus, the knowledge of 
whether MOPr trafficking is regulated by ARF1 or ARF6 might provide new insights into MOPr-
mediated signaling pathways and may lead to the identification of further regulatory proteins 
involved in the modulation of MOPr trafficking and signaling.  
Therefore, the aim of the present study is to determine which ARF protein, ARF1 or 
ARF6, is involved in opioid-mediated PLD2 activation and migth be a part of a hypothetical 
“ternary complex” which is formed between MOPr, PLD2 and ARF protein. We also investigated 
the main molecular mechanisms of ARF function in MOPr trafficking and signaling. 
The major goal of this thesis is to understand the mechanisms of endocytosis and 
trafficking of the µ-opioid receptor and to further investigate the role of the key players involved 
in regulation of these processes, mainly phospholipase D2 and ARF protein(s). As outlined 
before, opioid drugs such as morphine are well known for their ability to produce potent analgesia 
as well as such unwanted side effects like tolerance, physical dependence, respiratory suppression 
and constipation. Better understanding of MOPr pharmacology and signaling will contribute to 
the development of new opioid drugs and therapeutic approaches that will be able to overcome 
the problems of negative side effects in clinical applications of opioids and make them more 
useful in treatment of severe pain. 
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2. Materials and Methods 
 
2.1. Materials 
 
2.1.1. Lab instruments and equipment 
Item Company 
UV-visible Spectrophotometer Pharmacia Biotech, Germany 
Expert Plus Microplate Reader ASYS, Austria 
Leica TCS-NT laser-scanning confocal 
microscope 
Leica Microsystems, Germany 
PTC-0200 DNA Engine PCR mashine MJ Research, Inc. USA 
Electrophoresis power supply Bio-Rad 
Gel electrophoresis system Bio-Rad 
Semi-dry Transfer Cell and Western blot 
system 
Bio-Rad 
Flasks, plates and dishes for cell culture Greiner Bio-One, Frickenhausen, Germany 
 
 
2.1.2. Kits and enzymes  
 
Product Company 
Endonucleases (Restriction enzymes)  New England Biolabs 
Taq DNA polymerase & PCR Kit Promega 
T4 DNA ligase  New England Biolabs 
Pfu DNA polymerase  Fermentas 
Oligonucleotides (Primers)  Metabion International AG, 
Germany 
Plasmid Mini Kit, Plasmid Midi Kit, PCR purification 
Kit, Gel Extraction Kit 
Qiagen, Germany 
Cyclic AMP (
3
H) assay system Amersham Biosciences, 
Braunschweig, Germany 
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2.1.3. Molecular weight markers  
 
DNA and protein molecular weight markers  Company 
GeneRuler
TM 
1kb DNA Ladder Fermentas 
Precision Plus Protein
TM
 Standards Bio-Rad 
 
2.1.4. Plasmids 
Plasmid Company or kindly provided by: 
pEAK10:HA-MOPr  
pcDNA3:T7-MOPr 
from Dr. T. Koch (IPT, Magdeburg, Germany) 
 
pcDNA3.1:PLD2 from Dr. S. Ryu (Pohang, South Korea) 
pCMV5:HA-ARF6/T44N, 
pCMV5:HA-ARF6/N48I,  
pCMV5:HA-ARF6/T157N 
from Dr. J. Jaworski (IIMBC, Warsaw, Poland) 
 
pXS:HA-ARF1/T31N 
from Dr. R. Mitchell (CIP, Edinburgh, UK) 
 
pGEM-T easy vector Promega, Medison, USA 
pcDNA3.1 
c-myc-pcDNA3.1 
Invitrogen, Karlsruhe, Germany 
 
2.1.5. Bacterial and eukaryotic cell lines  
 
Cells Company 
E. coli XL1 blue Promega 
Human embryonic kidney (HEK) 293 cells 
German Collection Of 
Microorganisms and Cell Cultures, 
Braunschweig, Germany 
African green monkey kidney fibroblast (COS-7) cells Clontech 
 
 
2.1.6. Cell culture media, antibiotics and reagents for mammalian cells  
 
Item Composition  
HEK 293 cell culture 
medium 
Dulbecco‟s Modified Eagle‟s Medium (DMEM) (Lonza, Basel, 
Switzerland) and 10% fetal calf serum (FCS) (Bachem, 
Heidelberg, Germany) 
COS-7 cell culture 
medium 
DMEM, 10% FCS, 2 mM L-glutamine (Lonza, Basel, 
Switzerland), 100 U/ml penicillin and 100 μg/ml streptomycin 
(Sigma-Aldrich) 
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Poly-L-lysin  50 µg/ml poly-L-lysin (Sigma-Aldrich) in sterile PBS, pH 7.4  
Tripsin/EDTA 
0.5 mM ethylenediaminetetraacetic acid (EDTA) and 0.05% 
Trypsin 
UltraMEM  Cambrex Bio Science Verviers S.p.r.l., Verviers, Belgium 
Neurobasal Gibco (Invitrogen) 
HBSS Hank´s balanced salt solution, Cambrex Bio Science Verviers 
S.p.r.l., Verviers, Belgium 
G418 PAA Laboratories GmbH, Pasching, Germany 
Puromycin, Penicillin and 
Streptomycin 
Sigma-Aldrich 
 
2.1.7. Culture media and additives for bacteria  
 
Culture medium Composition 
LB-medium  20 g LB Broth Base (Invitrogen) / 1000 ml H2O  
LB-Agar  15 g Select Agar (Invitrogen) / 1000 ml LB-medium  
Ampicillin Sigma-Aldrich 
 
* All media were autoclaved at 121°C for 15 minutes. Antibiotic was added additionally after 
cooling down LB-agar media to 50-55ºC. 
 
2.1.8. Drugs and other chemicals 
 
Product Company 
Rhodamine-phalloidin Invitrogen, Karlsruhe, Germany 
Lipofectamine™ 2000 Invitrogen, Karlsruhe, Germany 
Protein A-agarose beads Amersham Biosciences, Braunschweig, Germany 
Triton-X 100 Merck, Darmstadt, Germany 
DPX mounting media Fluka, NeuUlm, Germany 
ABTS solution Roche Molecular Biochemicals 
Leupeptin, Pepstatin A, Aprotinin, 
Dithiotreitol 
Sigma-Aldrich 
HEPES Serva, Heidelberg, Germany 
DNase Sigma-Aldrich 
Bovine serum albumin (BSA) Serva, Heidelberg, Germany 
Enhanced chemiluminiscence 
detection system 
Amersham Biosciences, Braunschweig, Germany 
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Ammonium persulfate (APS) Sigma-Aldrich 
30% acrylamide mix Carl Roth Gmbh & Co 
TEMED Serva, Heidelberg, Germany 
Morphine 
[(D-Ala
2
,NMe-Phe
4
,Gly-ol
5
)-
enkephalin (DAMGO) 
Fagron GmbH & Co, KG, Barsbuettel, Germany 
Bachem, Heidelberg, Germany 
[
3
H]DAMGO NEN, Koeln, Germany 
Naloxone Pfitzer/Goedecke, Freiburg, Germany 
Forskolin Applichem, Darmstadt, Germany 
phorbol 12-myristate 13-acetate 
(PMA) 
Biomol International 
N-myristoylated (2-13) ARF6 peptide Calbiochem, Darmstadt, Germany 
Agarose Biozym 
[1,2,3-
3
H]glycerol (1µCi/ml; specific 
activity 40 Ci/mmol) 
American Radiolabeled Chemicals, St. Louis, MO 
 
 
2.1.9. Antibodies 
2.1.9.1. Primary antibodies for Western blot and immunostaining  
Antibodies Species WB dilution IF dilution Company 
anti-T7 antibody mouse 1:1000 1:1000 Novagen, Darmstadt, Germany 
anti-HA serum rabbit  1:300 Gramsch Laboratories, 
Schwabhausen, Germany 
anti-PLD2 antibody mouse  1:500 Invitrogen, Karlsruhe, Germany 
anti-c-myc antibody mouse  1:500 BD Biosciences, Heidelberg, 
Germany 
anti-ARF6 antibody mouse 1:100  Santa Cruz Biotechnology, USA 
anti-Rab11 antibody goat  1:100 Santa Cruz Biotechnology, USA 
anti-HA antibody rat 1:1000  Roche Applied Science, 
Mannheim, Germany 
anti-actin antibody rabbit 1:500  Santa Cruz Biotechnology, USA 
anti-actin antibody mouse 1:10000  Sigma-Aldrich 
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2.1.9.2. Secondary antibodies for Western blot and immunostaining  
 
Antibodies Species Dilution Company 
Anti-rabbit IgG, cyanine 3.18-
conjugated (Cy3) 
goat 1:1000 Dianova, Germany 
Anti-rabbit IgG, Alexa Fluor
TM
 
488 and 647 conjugated  
goat 1:1000 and 1:500 Molecular Probes, Invitrogen 
Anti-goat IgG, Alexa Fluor
TM
 
647 conjugated 
donkey 1:500 Molecular Probes, Invitrogen 
Anti-rabbit IgG, peroxidase-
conjugated  
goat 1:5000 Amersham Biosciences, 
Braunschweig, Germany 
Anti-mouse IgG, peroxidase-
conjugated 
sheep 1:5000 Amersham Biosciences, 
Braunschweig, Germany 
Anti-rat IgG, peroxidase-
conjugated 
goat 1:5000 Amersham Biosciences, 
Braunschweig, Germany 
 
2.1.10. Buffers and Solvents 
 
 Zamboni’s fixative: 
  4% paraformaldehyde and 0.2% picric acid in phosphate buffer, pH 6.9 
 
 Radioimmunoprecipitation (RIPA) buffer: 
50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 10 mM NaF, 10  mM 
disodium pyrophosphate, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% 
SDS and the following proteinase inhibitors: 0.2 mM phenylmethylsulfonyl 
fluoride, 10 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 µg/ml aprotinin and 10 
µg/ml bacitracin. (Proteinase inhibitors were added prior to use). 
 
 SDS-sample buffer: 
62.5 mM Tris-HCl, pH 6.8, 2% SDS, 20% glycerol, 0.005% bromphenol blue, 
100 mM dithiotreitol (dithiotreitol was added prior to use)   
 
 1 x TPBS (Tris/phosphate-buffered saline): 
10 mM Tris, 10 mM phosphate buffer, 137 mM NaCl and 0.05% thimerosal, pH 
7.4 
 
 1 x PBS (phosphate-buffered saline): 
137 mM NaCl,  2.6 mM KCl,  8.1 mM Na2HPO4,  1.4 mM KH2PO4,  pH 7.4 
  
 1 x PBS/Tween 20: 
  137 mM NaCl,  2.6 mM KCl,  8.1 mM Na2HPO4,  1.4 mM KH2PO4,  pH 7.4 and                                    
                           0.01% Tween 20 
 
 1 x TAE (Tris-acetate-EDTA) buffer: 
  40 mM Tris, 0.2 mM acetic acid, 1 mM EDTA, pH 7.6 
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2.2. Methods 
 
2.2.1. cDNA cloning into expression vectors  
 
In the following experiments, gene subcloning was carried out using standard molecular 
cloning protocols or according to the manufacturer‟s instructions. Briefly, genes or DNA 
fragments of interest were amplified by polymerase chain reaction (PCR). Following 1% agarose 
gel electrophoresis in TAE buffer, the fragments were purified by the PCR Purification Kit. The 
fragments were then subjected to appropriate enzymatic digestion (2 hours or overnight at 37ºC) 
and ligated with T4 ligase to the pre-digested vector. The ligations were performed at room 
temperature for 1.5 hour. To select the positive clones, obtained constructs were transformed into 
freshly generated E. coli XL1 Blue competent cells by heat-shock transformation for subsequent 
DNA mini-prep isolation. Extracted DNA from isolated clones was incubated with restriction 
enzymes and the positive clones showing the insert with the expected molecular size were 
identified by 1% agarose gel electrophoresis. The identity of these clones was subsequently 
confirmed by sequence analysis (Seqlab Göttingen). For mammalian cell transfection, DNA with 
high concentration and purity was prepared using the Plasmid Midi Kit. The DNA concentration 
was determined by spectrophotometrical quantification at 260 nm. 
 
2.2.2. Cell culture, transfection  and generation of stable cell lines 
2.2.2.1. Human embryonic kidney (HEK) 293 cells 
 
HEK293 cells were maintained in DMEM medium supplemented with 10% FCS in a 
humidified incubator with an atmosphere containing 10% CO2, at 37ºC. All transfections were 
done using Lipofectamine
TM 2000 according to manufacturer‟s instructions. For HEK293 stable 
cell line expressing T7-MOPr, the cells were transfected with pcDNA3:T7-MOPr plasmid 
containing G418 resistance gene. Stable transfectants were then selected in the presence of 
1mg/ml G418. For generation of stable cell line coexpressing HA-MOPr and PLD2 that was used 
for PLD2 assay, HEK293 cells were first transfected with pEAK10:HA-MOPr plasmid 
containing puromycin resistance and stable transfectants were selected in the presence of 1µg/ml 
puromycin. The cells were then subjected to second round of transfection with pcDNA3.1:PLD2 
plasmid and selected in the presence of 1µg/ml puromycin and 500 µg/ml G418. The whole pool 
of resistant cells was used without selection of individual clones. Receptor and/or PLD2 
expression was monitored using receptor ligand binding assays, PLD assays, Western blot 
analysis and confocal microscopy as described below. 
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Transient transfection of T7-MOPr-expressing HEK293 cells with HA-ARF mutants was 
done using Lipofectamine
TM
 2000 in 6-well plates in reverse manner. Suspension of cells 
(approximately 80% confluence) in DMEM/10% FCS was mixed with DNA-Lipofectamine 2000 
complexes prepared according to manufacturer‟s instructions prior to plating. After 5-6 h, 
medium was changed with fresh DMEM/10% FCS. 24 h after transfection, cells were seeded for 
further experiments. Confocal microscopy analysis revealed that about 50% of the cells expressed 
both proteins.  
 
2.2.2.2. African green monkey kidney fibroblast (COS-7) cells 
 
COS-7 cells were were maintained in DMEM medium supplemented with 10% FCS, 2 
mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin in a humidified incubator with 
an atmosphere containing 5% CO2, at 37ºC. Transient co-transfection of these cells with 
pcDNA3:T7-MOPr and HA-ARF6 mutants was done using Lipofectamine
TM
 2000 in 6-well 
plates in reverse manner as described above. 24 h after transfection, the cells were seeded for 
further experiments. 
 
2.2.2.3. Primary neuronal cell cultures 
 
 Neuronal cultures were prepared from rat cortex of E17 Sprague Dawley rat embryos 
(Charles River). Dissection medium consisted of Hans balanced salt solution (HBSS) with 20 
mmol/L HEPES, pH 7.3. The cerebral cortex was dissected and then incubated for 15 min at 37ºC 
in dissection medium containing 0.05% (w/v) trypsin and 0.5 mmol/L EDTA. Trypsinization was 
terminated using dissection medium containing 0.5 mg/ml trypsin inhibitor, 0.24 mg/ml DNase 
and 3 mg/ml BSA. The tissue was rinsed with dissection medium, triturated, centrifuged and 
resuspended in dissection medium. All animal procedures were approved by Otto-von-Guericke 
University, Magdeburg.  
About 3x10
5
 freshly prepared cortical cells were seeded onto poly-L-lysine-treated 
coverslips in 12-well plates and grown for 4 days in Neurobasal medium supplemented with 2% 
B-27, 0,5 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. The cells were 
cultured at 37ºC and 5% CO2 in a humidified incubator. On the 4
th
 day after seeding the medium 
was removed and saved in a tube at 37ºC to be used again after transfection. The cells were then 
transfected with peak10:HA-MOPr plasmid alone or together with pcDNA3.1:c-myc-
ARF6/T44N or pcDNA3.1:c-myc-ARF6/T157N plasmid using Lipofectamine
TM
 2000 according 
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to manufacturer‟s instructions. 5-6 h after transfection medium was changed and used 
(conditioned) medium was put back onto cells. Immunocytochemistry was done 48 h after 
transfection. 
 
2.2.3. RNA interference (RNAi) 
2.2.3.1. Principle 
 
RNA interference (RNAi) is the process of mRNA degradation that is induced by double-
stranded RNA (dsRNA) in a sequence-specific manner. In the laboratory, RNAi is designed and 
used for specifically silencing the expression of any gene for which sequence is available in order 
to investigate the influence of specific gene knock-down on some cellular processes. 
First, the dsRNAs that were introduced into the cell by different mechanisms get 
processed into 20-25 nucleotide long small interfering RNAs (siRNAs) by an RNase III-like 
enzyme called Dicer (initiation phase) (Figure 2.1.). Alternatively, siRNAs can be introduced into 
the cell directly. Then, the siRNAs assemble into endoribonuclease-containing complexes known 
as RNA-induced silencing complexes (RISCs), unwinding in the process. The siRNA strands 
subsequently guide the RISCs to complementary RNA molecules, where they cleave and destroy 
the cognate RNA (effector phase). Knock down of the specific gene expression is usually 
detected on RNA level (by RT-PCR) or protein level (by Western blot analysis).  
                 
 
Figure 2.1. The Mechanism of RNA interference. See text for details. 
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2.2.3.2. Procedure 
 
 To design ARF6-specific siRNA duplexes, the nucleotide sequence of human ARF6 gene 
was screened for unique 21-nucleotide sequence starting with two adenosines (AA) and 
containing a G/C ratio of 30-50%. The following 21-nucleotide sequence was chosen 
corresponding to the position 244-265 on the human ARF6 mRNA relative to the start codon: 5‟-
AAGGUCUCAUCUUCGUAGUGG-3‟. Similarly, the following sequence targeting ARF1 gene 
was used as a control: 5‟-ACCGTGGAGTACAAGAACA-3‟. The sequences were compared 
with the human genome data base using BLAST and no homology was found with other genes. 
Non-specific control sequence was 5‟-AGGUAGUGUAAUCGCCUUGTT-3‟. All sequences 
were manufactured by Eurofins MWG Operon, Ebersberg, Germany and their efficiency in 
protein knock down was tested by Western blot analysis as described.  Briefly, due to initial 
problems in detection of endogenous ARF proteins with commercially available antibodies that 
we tested, first siRNA efficiency tests were done with overexpression of HA-tagged ARF 
proteins. Namely, HEK293 cells stably expressing T7-MOPr were transiently co-transfected with 
wild type HA-ARF1 and HA-ARF6 in combination with two different concentrations of indicated 
siRNAs. 48 h after the transfection, the cells were lysed and lysate was directly tested in Western 
blot analysis using rat anti-HA antibody (1:1000). The efficiency of ARF6 siRNA to knock down 
the expression of endogenous ARF6 protein was then reconfirmed without overexpression of 
ARF6 protein using anti-ARF6 antibody (1:100). For quantitative assays, the transfection of T7-
MOPr-expressing HEK293 cells with appropriate siRNAs was done in 6-well plates with 
Lipofectamine
TM
 2000 according to manufacturer‟s instructions. 24 h after transfection the cells 
were seeded in 48-well plates and one day later tested in ELISA assay. 
 
2.2.4. Radioligand binding assay 
 
The binding characteristics of the receptor in cells expressing MOPr alone or together 
with PLD2 were determined by saturation binding assays on membranes prepared from stably 
transfected HEK293 cells. For whole cell binding, 10
6
 cells were incubated with at least six 
different  concentrations of [
3
H]DAMGO in a range from 0.3 to 9 nm for 40 min at 25ºC in 50 
mM Tris-HCl, pH 7.8. Cells were collected on GF 10 glass-fiber filters and unbound ligand was 
removed by extensive washing with 50 mM Tris-HCl, pH 7.8. The radioactivity of the filters was 
determined by liquid scintillation counting. Specific binding was calculated by subtracting 
nonspecific binding from total binding. Nonspecific binding was determined as radioactivity 
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bound in the presence of 1 µM unlabelled DAMGO. Results were calculated as fM bound 
radioligand per mg of protein, measured by Lowry method. The dissociation constant (KD) and 
number of [
3
H]DAMGO binding sites (Bmax) were calculated by Scatchard analysis.  
 
2.2.5. Transphosphatidylation reaction – PLD assay 
2.2.5.1. Principle 
 
 PLD catalyzes hydrolysis of the distal phosphodiester bond in phospholipids such as 
phosphatidylcholine (PC), the most abundant phospholipid in biological membranes. A 
phosphatidyl-enzyme intermediate that is transiently formed is normally hydrolysed by water, 
generating phosphatidic acid (PA). Primary short chain alcohol ethanol can substitute water in a 
competing transphosphatidylation reaction giving rise to phosphatidylethanol (PtdEtOH)  (Figure 
2.2.). This reaction occurs at the expense of the hydrolytic reaction decreasing PA formation. 
Phosphatidylalcohols are metabolically stable and would accumulate in cells upon PLD 
activation. Since cellular phosphatidylalcohol levels are extremely low, its accumulation upon 
PLD activation is readily detectable and can be used as a marker of PLD activation. 
              
Phosphatidylcholine (PC)
Transphosphatidylation
(Alcohol)
Hydrolysis
(H2O)
Phosphatidylalcohol Phosphatidic acid (PA)
 
 
Figure 2.2. Hydrolysis and transphosphatidylation of phosphatidylcholine by phospholipase 
D2.  X- the rest of alcohol, e.g. C2H5 for ethanol.                      
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2.2.5.2. Procedure   
 
 HEK293 cells stably coexpressing MOPr and PLD2 were transiently transfected with 
indicated ARF mutants as described above and seeded into 6 cm dishes. 24 h after transfection, 
the cells were kept for 24 h in serum-free UltraMEM medium containing [1,2,3-
3
H]glycerol 
(1µCi/ml; specific activity 40 Ci/mmol) in order to label phospholipids. The cells were then 
treated for 30 min at 37ºC with indicated substances (1µM DAMGO, 1µM morphine or 1µM 
PMA) in serum-free UltraMEM containing 2% ethanol. After stimulation, the cells were 
extracted in 2.5 ml of ice-cold methanol/water mixture (3:2, v/v). Subsequently, 1.5 ml 
chlorophorm and 0.35 ml H2O were added giving the final ratio methanol:chlorophorm:water = 
10:10:9, v/v/v. The lower, lipid phase was separated by thin layer chromatography. Individual 
phospholipids were stained with iodine, identified by standards and spots corresponding to 
PtdEtOH, PA and PC were isolated and subjected to liquid scintillation counting.  PLD activity 
was calculated as percentage [
3
H]- PtdEtOH of the total cellular PC concentration and then shown 
as the percent of the control values.   
 
2.2.6. Quantitative analysis of receptor internalization and recycling by Enzyme-linked 
Immunosorbent Assay (ELISA) 
 
 24 h after transfection with ARF mutants or adequate siRNAs, T7-MOPr-expressing 
HEK293 cells were seeded in DMEM medium supplemented with 10% FCS and grown onto 
poly-L-lysine-treated 48-well plates overnight. In experiments with N-myr-ARF6, DMEM 
medium was also supplemented with 25 µM N-myr-ARF6 peptide. To estimate endocytosis, the 
cells were specifically surface labeled with T7-antibody (1:1000) in UltraMEM  for 1.5 h at 4°C 
and after washing stimulated with indicated agonists for 30 min at 37°C. After fixation, the cells 
were incubated with anti-mouse peroxidase-conjugated secondary antibody (1:5000) for 2h at 
room temperature. Plates were developed with 150 µL of ABTS solution per well. After 20-30 
min, 100 µL of the substrate solution from each well was transferred to a 96-well plate. Color 
reaction was analyzed at 405 nm using an Expert Plus Microplate Reader. During the assay, the 
cells were kept on 4ºC for 30 min (4ºC control), treated with indicated agonists in UltraMEM for 
30 min at 37°C or not treated (37ºC control). Constitutive endocytosis in the absence of agonist 
was calculated as percentage loss of surface receptors in 37ºC control to 4ºC control. Agonist-
induced receptor endocytosis was calculated by subtraction of constitutive endocytosis from total 
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endocytosis that was detected in agonist-treated samples in comparison to 4ºC control (100%), or 
total endocytosis was shown as indicated.  
To measure recycling, after 30 min of DAMGO treatment the cells were washed with 
warm media to remove the agonist and then incubated for further 30 min at 37°C in the presence 
of 1 µM receptor antagonist naloxone in order to block residual DAMGO-stimulated endocytosis 
of MOPr. After fixation of cells, surface receptors were detected as described in this section. In 
these experiments, 37ºC control that was taken as 100% for calculation of receptor endocytosis in 
agonist-treated samples. The recycling of internalized receptor was estimated as the percentage of 
recovered surface receptors from endocytosed receptors.  
 
2.2.7. Immunocytochemistry 
2.2.7.1. HEK293 cells 
 
24 h after transfection, HEK293 cells coexpressing T7-MOPr and various HA-ARF 
mutants were seeded on poly-L-lysine-coated coverslips and grown overnight. After surface 
labeling of receptors with T7-antibody (1:1000) for 1.5 h at 4°C, the cells were washed and 
stimulated or not with indicated agonists at 37°C for 30 min and then fixed with Zamboni‟s 
fixative for 30 min at room temperature. After washing several times with TPBS, the cells were 
then permeabilized by 3 min subsequent incubation with 50% and 100% methanol. To visualize 
cells transiently transfected with ARF mutants, cells were further incubated with 1 µg of affinity 
purified rabbit anti-HA antibody for 1.5 h at room temperature. Bound primary antibodies were 
detected using anti-mouse cyanine 3.18-conjugated secondary antibody and/or anti-rabbit Alexa 
488-conjugated secondary antibody. Cells were permanently mounted in DPX and examined 
using Leica TCS-NT confocal microscope. Images were recorded digitally and processed using 
ImageJ NIH (National Institute of Health) and Adobe Photoshop CS (version 9.0 CS2). 
 
2.2.7.2. COS-7 cells 
 
24 h after transfection, COS-7 cells coexpressing HA-MOPr and indicated ARF6 mutants 
were seeded on poly-L-lysine-coated coverslips and grown overnight. In these experiments 
different combinations of triple immunostaining were done as indicated. In some cases, MOPr 
receptors were first surface labeled with anti-HA serum (1:300) for 20 min at room temperature 
and then the cells were washed and stimulated or not with 10 µM DAMGO at 37°C for 30 min. In 
recycling experiments, after stimulation the agonist was washed away and the cells were treated 
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for further 30 min (during receptor recycling) with 1µM receptor antagonist naloxone in order to 
block residual DAMGO-stimulated endocytosis of MOPr. After fixing with Zamboni‟s fixative 
for 30 min at room temperature, the cells were permeabilized with 5 min incubation with 0.3% 
Triton X-100 in PBS at room temperature. Blocking was done by 1 h incubation with 1% NGS at 
room temperature. Subsequently, HA-ARF6 mutants or Rab11 protein were immunostained with 
primary antibodies (1 µg of affinity purified rabbit anti-HA antibody or anti-Rab11 antibody, 
1:100) and then visualized by 1.5 h incubation with a mixture of appropriate secondary antibodies 
at room temperature. Finally, actin cytoskeleton was detected by 20 min incubation with 
rhodamine-phalloidin according to manufacturer‟s instructions. Cells were permanently mounted 
in DPX and examined using Leica TCS-NT confocal microscope.  
 
2.2.7.2.1. Transferrin trafficking-“pulse-chase” assay 
 
  In COS-7 cells co-transfected with HA-MOPr and “GTP-locked” ARF6 mutant a 
previously described “pulse-chase” assay (Tsao and von Zastrow, 2000; Tulipano et al., 2004) 
was done. Here the degree to which a “pulse” of internalized MOPr was accessible to a 
subsequent “chase” of endocytosed transferrin was estimated.  
24 h after transfection, COS-7 cells coexpressing HA-MOPr and “GTP-locked” ARF6 
mutant were seeded on poly-L-lysine-coated coverslips and grown overnight. First, MOPr was 
surface labeled with anti-HA serum like described above and then the cells were stimulated or not 
with 10 µM DAMGO for 30 min at 37°C to drive internalization of antibody-labeled receptor. 
After washing, the cells were incubated with UltraMEM containing 5 µg/ml Alexa Fluor-
conjugated transferrin for 20 min at 37°C. These conditions label both early and recycling 
endosomes (Dunn et al., 1989). The cells were then fixed and permeabilized and antibody-labeled 
receptor as well as actin cytoskeleton were detected like described above. 
 
2.2.7.3. Neuronal cultures 
 
Immunocytochemistry was done 48 h after transfection of primary cultured corical 
neurons with HA-MOPr and c-myc-ARFs. First, MOPr was surface labeled with anti-HA serum 
(1:300) for 20 minutes at room temperature. The cells were then washed with UltraMEM, treated 
or not with 10 µM DAMGO or 10 µM morphine for 30 minutes at 37ºC, fixed with Zamboni‟s 
fixative and permeabilized with methanol like described above. After blocking with 10% NGS in 
PBS for 1 h, ARFs were immunostained with c-myc antibody (1:500) in 3% NGS for 1.5 h at 
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room temperature. The proteins were visualized after 1.5 h incubation at room temperature with 
mixture of appropriate secondary antibodies using Leica TCS-NT confocal microscope. 
For quantification of subcellular fluorescent density, NIH Image 1.62 software was used 
as previously described (Schröder et al., 2009). Briefly, cytosolic fluorescent intensity was 
substracted from whole cell fluorescent intensity to obtain surface fluorescent intensity. 
Fluorescent intensity values were divided per surface unit (pixel) to obtain densities. Ratios of 
cytoplasmic (Df cyto) versus surface (Df surf) fluorescence densities were calculated to normalize 
data across neurons examined. A value of 1.0 results from equal densities of MOPr in the 
cytoplasm and at the cell surface. 
For desensitization studies, the newly prepared cortical cells were transfected with the 
catalytically inactive (K758R) PLD2 mutant (nPLD2) (Koch et al., 2006) after 4 days in culture 
using Lipofectamine 2000 according to manufacturer‟s instructions. Two days later cAMP levels 
were determined as described below under “Materials and Methods” (2.2.9.). As a control, 
untransfected cells were assayed after 6 days in culture. 
 
2.2.8. Western blot analysis 
 
 Depending on the experiment, 24 or 48 h after transfection of HEK293 cells stably 
expressing T7-MOPr with indicated plasmids or siRNAs, the cells were washed one time with 
PBS and RIPA buffer was added (1.5 mL per flask or 250 µL per well of 6-well-plate). The cells 
were swollen for 15 min on ice and then homogenized and scraped into eppendorf tube. After 30-
40 min of gentle shaking at 4ºC, samples were centrifuged at 18000 rpm for 1h at 4ºC, the 
supernatant was collected and either used immediately or aliquoted and frozen at -80ºC. Before 
loading onto gel, samples were prepared by adding appropriate amounts of SDS-sample buffer 
(plus freshly added DTT) and then cooked for 5 min at 95ºC.    
 Proteins were separated using one-dimensional 8% or 15% sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) under fully denaturing and reducing conditions 
(Laemmli system). Gels were allowed to run at voltage of 100-150 mV in an electrophoresis 
chamber (Bio-Rad) filled with 1 x Laemmly buffer. Subsequently, proteins were electrotransfered 
from polyacrylamide gels to nitro-cellulose membranes (Amersham Biosciences) using Semi-dry 
Transfer Cell and Western blot system (Bio-Rad). After 1-1.5h blocking in 5% milk in 
PBS/Tween 20, the membrane was washed three times with PBS/Tween 20 for 3 minutes. Blots 
were incubated at 4°C overnight with the primary antibody diluted in PBS/Tween 20 or in 5% 
milk in PBS/Tween 20, depending on the antibody. After five times washing with PBS/Tween 20 
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for 5 min each time, the membrane was then submerged in appropriate secondary antibody 
(depending on the nature of the primary antibody) for 90 minutes at room temperature in 
PBS/Tween 20 or in 5% milk in PBS/Tween 20. After washing the blot as describe above, 
immunoreactive bands were visualized using the enhanced chemiluminescence (ECL) 
detection system.  
 
2.2.9. Determination of receptor desensitization by measurement of cAMP 
accumulation 
 
The cells were seeded at a density of approximately 1x10
5
 per well and grown onto poly-
L-lysine-treated 24-well plates overnight. For testing ARF6 mutants, experiment was done 48h 
after transfection. On the day of the assay, the cells were preincubated at 37ºC with UltraMEM 
containing either 1 µM DAMGO or 1 µM morphine up to 2 hours to induce receptor 
desensitization. After washing with DMEM, the cells were incubated for another 15 min with 
DMEM containing either 5 µM or 25 µM forskolin, for neuronal cultures and HEK293 cells, 
respectively, or combination of forskolin and the previously used agonist. After washing the cells 
one time with ice-cold PBS, the intracellular cAMP was extracted immediately with 0.5 ml of 
ice-cold HCl/ethanol (1 volume of 1N HCl/100 volumes of ethanol, stored at -20ºC). The 
supernatant was transferred into a 1.5 ml tube and then evaporated by vacuum centrifugation. The 
residue of cAMP was frozen at -20ºC or the extracted cAMP content was determined using a 
commercially available cAMP (
3
H) radioassay kit. Maximum agonist-induced inhibition of 
cAMP accumulation without agonist preincubation has been defined as 100%. Receptor 
desensitization was measured as the decreased ability of the agonist to inhibit forskolin-
stimulated adenylate cyclase activity after extended agonist pretreatment.  
 
2.2.10. Data analysis 
 
 Statistic analysis of the data was done by one-way ANOVA followed by Bonferroni test 
or Student‟s t test as indicated using GraphPad Prism 4.0 software.  
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3. Results 
 
3.1. Overexpression of the dominant negative ARF6 mutant (DN-ARF6) decreases 
agonist-induced MOPr endocytosis in HEK293 cells 
 
Previous work from our group demonstrated that opioid-mediated activation of 
phospholipase D2 (PLD2) is dependent on ADP-ribosylation factor (ARF) proteins (Koch et al., 
2003). Since PLD2 activation is essential for µ -opioid receptor (MOPr) endocytosis (Koch et al., 
2003, 2006), we wanted to investigate in this study whether MOPr endocytosis is regulated via 
ARF proteins and to elucidate which ARF protein is involved, ARF1 or ARF6.  
To answer these questions, first we generated HEK293 cell line stably expressing T7-
tagged full length MOPr as described in “Materials and Methods” section. Stable transfectants 
were selected in the presence of 1 mg/ml G418 and the whole pool of resistant cells was used 
without selection of individual clones. Confocal analysis shown on Figure 3.1.a reveals a 
membrane expression of MOPr in untreated cells with very few intracellular vesicles containing 
constitutively internalized receptor. However, 30 min treatment of cells with 1µM of the receptor 
internalizing agonist DAMGO [(D-Ala
2
,NMe-Phe
4
,Gly-ol
5
)-enkephalin] induced massive 
endocytosis of antibody-labeled MOPr to clusters of intracellular vesicles, as expected. This cell 
line stably expressing T7-MOPr alone was used in further experiments as a control. 
 To investigate the effects of ARF1 and ARF6 on MOPr trafficking, next we transiently 
transfected T7-MOPr expressing HEK293 cells with HA-tagged dominant negative ARF mutants 
DN-ARF1 (ARF1/T31N; Dascher and Balch, 1994) or DN-ARF6 (ARF6/T44N; Macia et al, 
2004). These mutants are commonly used to block ARF function since they cannot exchange 
GDP to GTP and therefore are trapped in their GDP-bound, inactive state. 48 h after transfection, 
the cells were treated or not with 1 µM DAMGO for 30 min at 37ºC and the effects of ARF 
mutants on MOPr endocytosis were analyzed using immunocytochemistry and quantitative 
ELISA assay.  
Protein expression of the HA-tagged ARF mutants was determined by immunostaining 
using anti-HA antibody which revealed that in all experiments about 50% of the cells were 
transfected and expressed HA-epitope. When investigating the effects of ARF mutants on MOPr 
endocytosis, only the cells that show ARF immunostaining were examined (Figure 3.1.b). Data 
show that blocking ARF6 but not ARF1 function significantly impaired agonist-induced MOPr 
endocytosis (Figure 3.1.b). It can be seen that in cells co-transfected with MOPr and DN-ARF6 
mutant most of the receptor stayed in the plasma membrane after DAMGO treatment and much 
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less receptor was internalized in comparison to the control cells expressing MOPr alone (Figure 
3.1.a) or to the adjacent cell that is not co-transfected with the mutant (Figure 3.1.b, see ARF 
immunostaining). On the other hand, overexpression of DN-ARF1 had no significant effect on 
MOPr endocytosis (Figure 3.1.b, upper panels).  
 
                     
Figure 3.1. Reduction of DAMGO-induced MOPr endocytosis by DN-ARF6 overexpression 
in HEK293 cells. Control HEK293 cells stably expressing T7-tagged MOPr alone (a) or cells 
coexpressing T7-tagged MOPr and HA-tagged DN-ARF1 or DN-ARF6 mutant (b) were treated 
or not with 1 µM DAMGO for 30 min at 37ºC. After immunostaining, the distribution of MOPr 
and ARFs was examined by fluorescent microscopy as described under “Materials and Methods”. 
Representative images from three independent experiments are shown. Note that in cells 
coexpressing MOPr and DN-ARF6 only cells that are transfected with ARF6 mutant show 
decreased endocytosis.  
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To confirm and further analyze the effects of DN-ARF1 and DN-ARF6 mutants on 
agonist-induced and basal (constitutive) endocytosis of MOPr, quantitative ELISA assay was 
done as described in “Materials and Methods”. The results revealed that blocking ARF6 function 
resulted in 50% decrease in the DAMGO-induced MOPr endocytosis (from 30% to almost 
15%) (Figure 3.2.a). This only partial inhibition of MOPr endocytosis by co-expression of the 
DN-ARF6 mutant might be due to the transient transfection efficacy of only about 50%. In all 
experiments, basal (constitutive) endocytosis in untreated cells was unaffected by expression of 
both ARF1 and ARF6 mutants (Figure 3.2.b), suggesting that binding of agonist to the MOPr is 
necessary for the effects of ARF protein to occur. These data demonstrated that ARF6 and not 
ARF1 protein is involved in regulation of agonist-induced MOPr endocytosis since blocking 
ARF6 function by overexpression of DN-ARF6 mutant significantly decreased receptor 
internalization after DAMGO-treatment. 
        
Figure 3.2. Quantitative analysis of MOPr endocytosis in HEK293 cells transfected with 
DN-ARF1 and DN-ARF6 mutants. Quantification of (a) DAMGO-induced and (b) basal 
(constitutive) MOPr endocytosis was done by ELISA assay as described under “Materials and 
Methods”. DAMGO-induced endocytosis was calculated by subtracting basal (constitutive) 
endocytosis from total endocytosis that was measured after DAMGO treatment and quantified as 
the percent loss of cell surface receptors. Data are presented as means ± SEM of 4-6 independent 
experiments performed in triplicate. ** p<0.01 versus MOPr alone was calculated by one-way 
ANOVA followed by Bonferroni test.  
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3.2. Knocking down the expression of endogenous ARF6 by siRNA decreases agonist-
induced MOPr endocytosis in HEK293 cells 
 
To confirm the results from previous section, we did similar experiments in HEK293 
cells stably expressing T7-MOPr after knocking down the endogenous ARF1 and ARF6 protein 
expression using siRNA technology. Western blot analysis shown on Figure 3.3.a demonstrates 
the efficiency of siRNAs that were used. Due to the initial problems in detection of endogenous 
ARF proteins with commercially available antibodies that we tested, Western blot analysis was 
first done in cells overexpressing HA-tagged wild type ARFs as described in “Materials and 
Methods” section. Detection was done from cell lysate directly using anti-HA antibody. 48 h after 
co-transfection of cells with wild type HA-ARFs and indicated concentrations of appropriate 
siRNAs, dose-dependent reduction of ARF protein level was detected. Further analysis revealed 
that cells transfected with 150 pM and 300 pM ARF6 siRNA decreased ARF6 expression for 
~50% and ~80%, respectively, compared to the control cells transfected with wild type HA-ARF6 
alone. For ARF1, the reduction of protein expression with the same concentrations of ARF1 
siRNA were ~70% and ~95%, respectively. Representative Western blots from three separate 
experiments are shown on Figure 3.3.a. These data show that the siRNAs used show high 
efficiency in knocking down the expression of appropriate proteins. 
To confirm that ARF6 protein is endogenously expressed in HEK293 cells and to be sure 
that used ARF6 specific siRNA can knock down the expression of endogenous ARF6 protein as 
well, we repeated again similar experiment without overexpression of ARF6 protein. Although 
previous studies have demonstrated the endogenous expression of ARF6 in HEK293 cells 
(Houndolo et al., 2005; Cotton et al., 2007), the amount of the protein seems to be quite low and 
from all commercially available anti-ARF6 antibodies that we tested, in our hands only one 
turned out to be specific and sensitive enough to detect the endogenous levels of ARF6 protein in 
this cell line. HEK293 cells stably expressing T7-MOPr were transfected or not (control) with 
150 pM and 300 pM ARF6 specific siRNA or 150 pM and 300 pM of non-specific siRNA control 
as indicated (Figure 3.3.b). 48 h after transfection the cells were lysed and tested in Western blot 
analysis using ARF6 specific mouse monoclonal antibody (1:100, Santa Cruz Biotechnology, 
Inc). It can be seen that although the endogenous levels of ARF6 are quite low, they can be 
clearly decreased with used ARF6 specific siRNA in concentration-dependent manner, as 
expected (Figure 3.3.b). Further analysis showed that transfection of cells with 150 pM ARF6 
specific siRNA resulted in ~50% decrease in ARF6 protein expression, while 300 pM ARF6 
specific siRNA decreased the amount of endogenous ARF6 protein for ~70%.  As expected, both 
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concentrations of non-specific siRNA control were without effect on the level of endogenous 
ARF6 in this experiment, confirming again the specificity of ARF6 siRNA that we used. 
 
 
Figure 3.3. Western blot analysis of efficiency of ARF1 and ARF6 specific siRNAs. HEK293 
cells stably expressing T7-tagged MOPr were transfected with a) HA-tagged wild type ARF1 or 
ARF6 protein alone or together with indicated concentrations of appropriate siRNAs or b) only 
with indicated siRNAs in two different concentrations. 48 h after transfection, the cells were 
lysed as described in “Materials and Methods” and the cell lysate was blotted directly using anti-
HA antibody (a) or anti-ARF6 antibody (b). Shown are representative Western blots from three 
independent experiments. Concentration-dependent reduction of protein levels was detected (see 
text for details). Actin immunodetection of the same blot was done in order to show similar 
loading levels in all lines. 
 
 
Finaly, we tested the effects of endogenous ARF protein knock down on DAMGO-
induced MOPr endocytosis. These experiments were done without ARF protein overexpression 
and HEK293 cells stably expressing T7-MOPr were transfected or not (control) only with 150 
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pM or 300 pM of indicated siRNAs. Quantitative analysis on Figure 3.4. shows that siRNA-
mediated knock down of the endogenous ARF6 expression was able to decrease DAMGO-
induced MOPr endocytosis in concentration-dependent manner. This was not the case for ARF1 
specific siRNA as well as for non-specific siRNA control in both concentrations tested, 
confirming our suggestion that ARF6 and not ARF1 protein is involved in regulation of agonist-
induced MOPr endocytosis. 
    
Figure 3.4. Effects of siRNA-mediated protein knock down of endogenous ARF1 and ARF6 
protein on DAMGO-induced MOPr endocytosis in HEK293 cells. HEK293 cells stably 
expressing T7-tagged MOPr were transfected with indicated siRNAs in two different 
concentrations (c1=150 pM  and c2=300 pM). 48 h after transfection, quantitative analysis of 
DAMGO-induced MOPr endocytosis was done by ELISA assay as described under “Materials 
and Methods”. Data are presented as means ± SEM of 4-6 independent experiments performed in 
triplicate. * p<0.05 versus MOPr alone (control) was calculated by one-way ANOVA followed 
by Bonferroni test.  
 
 
3.3. Overexpression of DN-ARF6 decreases agonist-induced MOPr endocytosis in 
cultured primary cortical neurons 
 
Next, we tested these findings in cultured primary cortical neurons in order to assure that 
the effect of ARF6 on the agonist-induced endocytosis of MOPr was not an artifact of the 
HEK293 cell model system. Neuronal cultures were prepared from rat cortex of E17 Sprague 
Dawley rat embryos. After 4 days in vitro, the cells were co-transfected with HA-MOPr and c-
myc-DN-ARF6 plasmids as described (see “Materials and Methods”). 48 h later, the cells were 
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treated or not with 10 µM DAMGO, immunostained and then examined under the confocal 
microscope. As expected, control cells expressing MOPr alone had much more endocytotic 
vesicles with internalized receptors after DAMGO treatment than cells expressing both MOPr and 
DN-ARF6 (Figure 3.5.a). Moreover, more receptor is retained in the plasma membrane after 
blocking ARF6 function. Quantitative analysis was done by subcellular fluorescent density 
measurements as described in “Materials and Methods” section. In these experiments, basal 
(constitutive) endocytosis in untreated cells was also unaffected (Figure 3.5.b, quantitative data) 
like in the HEK293 cell model system (see Figure 3.2.b) and therefore not shown by 
immunocytochemistry. 
 
 
 
Figure 3.5. Coexpression of DN-ARF6 mutant decreases DAMGO-induced MOPr 
endocytosis in transfected cortical neurons. a) Newly prepared rat cortical neurons (E17) were 
transfected with HA-tagged MOPr alone (left panels) or HA-tagged MOPr and c-myc-tagged 
DN-ARF6 in combination (rigth panel). 48 h after transfection, the cells were treated or not with 
10 µM DAMGO for 30 min at 37ºC. After immunostaining, labeled receptors (green) and DN-
ARF6 mutant (magenta) were detected as described in “Materials and Methods” section. Shown 
are representative images from several independent experiments. b) Quantitative analysis of 
MOPr internalization: the values are expressed as ratio of cytoplasmic (Df cyto) versus surface 
(Df surf) fluorescent densities (n=10 per treatment) (see “Materials and Methods” section for 
details).  
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Moreover, it can be seen that by quantitative analysis we detected much higher block of 
endocytosis here than in experiments with HEK293 cells co-transfected with MOPr and DN-
ARF6 mutant (see Figure 3.2.a for comparison). The reason for this is the fact that in this case 
only the cells transfected with DN-ARF6 were used for calculation by subcellular fluorescent 
density measurement since they could be clearly identified under the microscope by ARF 
immunostaining. 
 
 
3.4. Expression of active ARF6 increases morphine-induced MOPr endocytosis in 
HEK293 cells and cultured primary cortical neurons 
 
Since blocking of ARF6 function leads to decrease in the amount of internalized MOPr 
after DAMGO treatment, we investigated next whether MOPr endocytosis can be increased by 
expression of an active ARF6 mutant. Besides the classical, constitutively active ARF6 mutant 
GTP-ARF6 (ARF6/Q67L; Peters et al, 1995) that is “locked” in its GTP-bound state, another 
active “fast cycling” ARF6 mutant FC-ARF6 (ARF6/T157N; Santy 2002; Klein et al., 2006) was 
recently characterized that can bind GTP and release GDP more quickly than the wild type ARF6. 
As mentioned in the “Introduction” section, several studies have shown that this mutant 
represents better the real active state of ARF6 small GTPase in the cells and prefer FC-ARF6 
over “GTP-locked” ARF6/Q67L mutant (Santy 2002; Klein et al., 2006, 2008). Therefore we 
used FC-ARF6 mutant in this set of experiments to investigate the effects of active ARF6 on 
agonist-induced MOPr endocytosis. 
HEK293 cells stably expressing T7-MOPr were transiently transfected or not (control) 
with FC-ARF6 mutant and 48 h after transfection MOPr endocytosis was investigated by 
immunocytochemistry and quantitative ELISA assay. Our results revealed that coexpression of 
FC-ARF6 mutant did not enhance the DAMGO-induced MOPr internalization significantly 
(Figure 3.6.a, quantitative data), presumably because DAMGO induces maximum endocytosis 
itself. Therefore we also treated the cells with 1 µM morphine, an agonist that is known to 
activate the MOPr without promoting efficient receptor endocytosis. Quantitative data on Figure 
3.6.a show that the constitutive endocytosis (without agonist treatment) was slightly increased in 
the untreated cells coexpressing MOPr and FC-ARF6 mutant. However, it is clear that only after 
stimulation with morphine MOPr endocytosis is significantly increased to more than 2-fold 
higher level than in control cells expressing MOPr alone. This suggests that a conformational 
change of the receptor induced by binding of an agonist is needed for the observed increase in  
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Figure 3.6. Expression of active FC-ARF6 mutant increases morphine-induced MOPr 
endocytosis. a) Control HEK293 cells stably expressing T7-tagged MOPr alone (left panels) or 
cells coexpressing T7-tagged MOPr and HA-tagged FC-ARF6 mutant (rigth panel) were treated 
with 1 µM morphine for 30 min at 37ºC. After immunostaining, the distribution of MOPr (upper 
panels) and FC-ARF6 (lower panel) was examined by fluorescent microscopy. Representative 
images from several independent experiments are shown. b) MOPr endocytosis after DAMGO 
and morphine treatment was quantified by ELISA assay as described under “Materials and 
Methods”. Receptor endocytosis was calculated as the percent loss of cell surface receptors. Data 
are presented as means ± SEM of three independent experiments performed in triplicate. * p<0.05 
versus MOPr alone (control) was calculated by Student's t test. 
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endocytosis in the presence of FC-ARF6. Moreover, the amount of internalized receptor after 
morphine treatment seemed to be dependent on the expression level of FC-ARF6 mutant, since 
cells with a high expression of FC-ARF6 showed more MOPr internalization than cells with a 
lower expression of this mutant (Figure 3.6.b, right panels). Similar results were obtained from 
primary cultured cortical neurons transfected with HA-MOPr and c-myc-FC-ARF6 (quantitative 
analysis, Figure 3.7.). Data show that expression of active "fast cycling" ARF6 mutant 
significantly increases morphine-induced MOPr endocytosis in this cellular system as well. These 
results further support our hypothesis and show that ARF6 protein plays a role in regulation of 
agonist-induced MOPr endocytosis. 
 
 
                   
Figure 3.7. Quantification of effect of active FC-ARF6 mutant on morphine-induced MOPr 
endocytosis in cultured primary cortical neurons. Quantitative analysis of MOPr 
internalization in transfected primary cultured cortical neurons: the values are expressed as ratio 
of cytoplasmic (Df cyto) versus surface (Df surf) fluorescent densities (n=10 per treatment) (see 
“Materials and Methods” section for details). 
 
                   
3.5. ARF6 function in the regulation of MOPr endocytosis is PLD2-mediated 
 
Next we investigated the molecular mechanisms by which ARF6 might facilitate MOPr 
internalization. Our previous studies have shown that opioid-mediated activation of PLD2 is 
ARF-dependent and essential for the induction of MOPr internalization (Koch et al., 2003, 2006). 
Namely, blocking PLD2 activity either by primary alcohols (such as 1-butanol) or expression of a 
nonfunctional N-terminal fragment of PLD2 significantly decreased MOPr endocytosis (Koch et 
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al., 2003, 2004). Moreover, expression of a catalytically inactive PLD2 mutant (K758R) was 
shown to block the agonist-induced MOPr endocytosis (Koch et al., 2006). Therefore, it is 
reasonable to suggest that the observed decrease of MOPr endocytosis by blocking ARF6 
function is due to an impaired PLD2 activation.  
Thus, to elucidate if ARF6 regulation of MOPr endocytosis is mediated via PLD2 
activation, we first tested if a PD-ARF6 (ARF6/N48I, Vitale et al., 2002) which is unable to 
activate PLD (“PLD-defective”) would also impair DAMGO-induced MOPr endocytosis. PD-
ARF6 mutant has been created and characterized as selectively incapable of activating PLD, 
whereas all other ARF6 functions remain unaffected in this protein. Namely, this mutant could be 
activated by ARNO and inactivated by Git1, an ARF6 GEF and a GAP, respectively, and 
remained able to stimulate PIP5K but not PLD. Therefore, PD-ARF6 mutant is a useful molecular 
tool for investigation of downstream effectors of ARF6 and has been already used to show that 
PLD plays a role in endosomal membrane recycling (Jovanovic et al., 2006).   
                                          
Figure 3.8. PD-ARF6 mutant overexpression reduces DAMGO-mediated MOPr 
endocytosis. HEK293 cells stably expressing T7-tagged MOPr were transiently transfected or not 
(control) with PD-ARF6 mutant. After 30 min of 1 µM DAMGO treatment, agonist-induced 
receptor endocytosis was determined by quantitative ELISA assay as described under “Materials 
and Methods”. Data are presented as means ± SEM of 3-5 independent experiments performed in 
triplicate. * p<0.05 versus control (MOPr alone) was calculated by Student's t test. 
 
 
As Figure 3.8. shows, coexpression of PD-ARF6 mutant together with MOPr in HEK293 
cells decreased receptor internalization to the levels comparable to those obtained after blocking 
ARF6 function by DN-ARF6 mutant overexpression (see Figure 3.2.a for comparison). Since PD-
ARF6 mutant is selectively incapable of activating PLD, whereas all other ARF6 functions 
Modulation of µ-opioid receptor signal transduction and endocytosis by ADP-ribosylation factor proteins 
- Results - 
 
- 43 - 
 
remain unaffected, it can be suggested that the main negative effects of blocking ARF6 function 
in regulation of MOPr endocytosis are due to impaired activation of PLD2 and not due to the 
blocking of other ARF6 effector functions. 
 It is also known that protein kinase C (PKC) is another pathway of PLD2 activation in 
vivo, besides ARF proteins. Thus, we further tested if ARF6 regulation of MOPr endocytosis is 
mediated via PLD2. Previous sections revealed that expression of DN-ARF6 or PD-ARF6 
mutants decreases agonist-induced MOPr endocytosis. If these effects are due to blocked PLD2 
activation, heterologous activation of PLD2 via PKC should restore DAMGO-induced MOPr 
endocytosis to the control levels in HEK293 cells coexpressing MOPr and DN-ARF6 or PD-
ARF6 mutant. Indeed, Figure 3.9.a-c shows that after 30 min co-stimulation of cells with 1 µM 
DAMGO and 0,1 µM PKC-activator PMA (phorbol 12-myristate 13-acetate), MOPr endocytosis 
in cells expressing both ARF6 mutants is rescued to the levels similar to those seen in the control 
cells. PMA treatment together with DAMGO had no significant effect on agonist-induced 
endocytosis in control cells expressing MOPr alone. Moreover, we show that this effect is not due 
to the increased PKC activity itself since PMA treatment alone did not induce significant MOPr 
endocytosis in both control cells and cells expressing ARF6 mutants. These results additionally 
demonstrate that the decrease in DAMGO-induced MOPr endocytosis detected after DN-ARF6 
expression might be due to a block of PLD2 activation. 
We also tested N-myristoylated ARF6 peptide (N-myr-ARF6) which consists of the N-
terminal region (amino acids 2-13) of ARF6 protein in endocytosis experiments. This cell-
permeable synthetic peptide has been previously reported to block PLD activity (Caumont et al., 
1998; Le Stunff et al., 2000). Figure 3.10. shows that overnigth treatment of T7-MOPr-expressing 
cells with N-myr-ARF6 leads to significant and concentration-dependent reduction of DAMGO-
induced receptor endocytosis. Confocal analysis shows a retention of the receptor in the plasma 
membrane of  HEK293 cells expressing T7-MOPr which were treated with N-myr-ARF6 peptide 
(Figure 3.10.a), meaning that less receptor is internalized in these cells in comparison to the 
control cells. Moreover, quantitative analysis on Figure 3.10.b shows that effect was present with 
both agonist concentrations tested (1 µM and 10 µM DAMGO) demonstrating strong inhibition. 
This experiment also confirmed our previous findings showing that blocking PLD2 activity 
significantly decreases agonist-induced MOPr endocytosis and stands in line with our data 
demonstrating that the function of ARF6 protein in regulation of MOPr endocytosis might be 
PLD2 mediated. 
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Figure 3.9. Effect of PMA-induced PLD2-activity on the DAMGO-mediated MOPr 
endocytosis in the presence of ARF6 negative mutants. HEK293 cells stably expressing T7-
tagged MOPr were transiently transfected or not (control) with DN-ARF6 or PD-ARF6 mutant. 
48 h after transfection surface receptors were labeled with T7-antibody and then the cells were 
treated for 30 min with the substances indicated. Receptor endocytosis was determined by 
quantitative ELISA assay as described under “Materials and Methods”. Note that PMA treatment 
together with DAMGO rescued MOPr endocytosis in the cells expressing DN- and PD-ARF6 
mutants to the levels similar to DAMGO-induced endocytosis in control cells expressing MOPr 
alone. In control cells, DAMGO + PMA treatment had no significant effect on MOPr endocytosis 
as well as PMA treatment alone in all cells used. Data are presented as means ± SEM of three 
independent experiments performed in triplicate. ** p<0.01 was calculated by one-way ANOVA 
followed by Bonferroni test.  
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Figure 3.10. N-myr-ARF6 peptide effects on DAMGO-induced MOPr endocytosis. T7-MOPr 
expressing cells were incubated or not (control) overnight with indicated concentrations of N-
myr-ARF6 peptide. The cells were treated with 1µM DAMGO (a) or 1 µM and 10 µM DAMGO 
(b) for 30 min and then immunocytochemistry (a) or quantitative analysis of endocytosis by 
ELISA (b) was done as described in “Materials and Methods” section. Note clear retention of 
receptor in the plasma membrane in cells treated with N-myr-ARF6 (a) as well as significant 
reduction of endocytosis with both concentrations of peptide and agonist tested (b). 
 
 
 
3.6. Role of ARF6 in opioid-mediated PLD2 activation 
 
Having in mind that both PMA as well as N-myr-ARF6 are unspecific substances that 
might induce various and multiple cellular responses that are not only dependent on PLD2 
activation, the following experiment was done in order to investigate the role of ARF6 in opioid-
mediated PLD2 activation. As a direct evidence that ARF6 protein modulates PLD2 activity, we 
measured opioid-mediated PLD2 activation using PLD assay in the presence of different ARF6 
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mutants. Evidence for an endogenous PLD2 expression and PLD activity in HEK293 cells has 
been provided in numerous publications (Rümenapp et al., 1997; Meier et al., 1999; Voss et al., 
1999). However, PLD2 levels in wild type HEK293 cells were below the detection limit of the 
transphosphatidylation assay used for measuring PLD activity. Therefore we first generated 
HEK293 cell line stably co-expressing HA-tagged MOPr and PLD2 as described under 
“Materials and Methods”. Briefly, HEK293 cells stably expressing HA-MOPr were generated 
and then subjected to the second round of transfection with plasmid containing PLD2 gene. 
Stable transfectants were selected in the presence of puromycin and G418 antibiotics and the 
whole pool of resistant cells was used without selection of individual clones. 
 MOPr and PLD2 expression was monitored by ligand binding experiments, Western blot 
and immunocytochemical analysis which showed membrane expression of both proteins, as 
expected. As shown in Table 1, saturation binding experiments (n=3) revealed no substantial 
differences between HA-MOPr and HA-MOPr-PLD2 expressing cells with respect to their 
affinities (KD) to [
3
H]DAMGO and their numbers of binding sites (Bmax). 
 
Stable cell line  KD (nM) Bmax (fM/mg) 
HA-MOPr 1±0.1 967±110 
HA-MOPr-PLD2 1.4±0.4 938±107 
 
Table 1. Functional properties of HA-MOPr and HA-MOPr-PLD2 stable cell lines. The KD 
and Bmax for the binding of [
3
H]DAMGO to MOPr in stable cell line expressing N-terminally HA-
tagged MOPr with or without co-expression of PLD2 in HEK293 cells were determined by 
Scatchard analyses as described in “Materials and Methods” section. Values shown are the means 
± SEM  of 3 independent experiments.  
 
The generated HEK293 cell line stably co-expressing MOPr and PLD2 was transiently 
transfected with indicated ARF mutants (DN-ARF1, DN-ARF6, PD-ARF6 and FC-ARF6) using 
Lipofectamine
TM
 2000 according to manufacturer's instructions. 24 h after transfection, the 
medium was changed into serum-free medium containing [1,2,3-
3
H]glycerol and the cells were 
kept in this medium overnight in order to label the newly synthesized phospholipids. On the day 
of the assay, the cells were stimulated with the serum-free medium containing 2% ethanol and 1 
µM agonists DAMGO or morphine or 0.1 µM PKC activator PMA for 30 min and individual 
phospholipids phosphatidylethanol (PtdEtOH), PA and PC were isolated as described (see 
“Materials and Methods”). The relative PLD2 activity was calculated as percentage [3H]- 
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PtdEtOH of the total cellular PC concentration and then shown as the percent of the control 
values. 
 As shown in Figure 3.11., treatment with the µ-agonist DAMGO resulted in a 2.5-fold 
increase in the PLD2 activity, whereas incubation with the noninternalizing agonist morphine 
failed to induce activation of PLD2, which is in line with our previous observations (Koch et al., 
2003). As mentioned above, it is known that besides ARFs, PKC is another pathway of PLD2 
activation in vivo. Indeed, activation of PKC by PMA promoted an almost 5-fold increase in the 
PLD2 activity, indicating a comparable PLD2 expression level in all tested MOPr expressing 
cells with and without co-expression of ARF mutants. Furthermore, DAMGO-mediated 
activation of PLD2 could be completely blocked in MOPr-PLD2 cells co-expressing the DN-
 
Figure 3.11. Effect of coexpression of ARF1 or ARF6 mutants on the opioid-induced PLD2 
activation measured by transphosphatidylation assay. MOPr-PLD2 expressing HEK293 cells 
were transfected with dominant negative ARF1 or ARF6 mutants as well as with "fast cycling" 
and "PLD-defficient" ARF6 mutant and then treated or not with 0.1 µM PMA, 1 µM DAMGO or 
1 µM morphine for 30 min as indicated. Then, PLD2 activation was determined as described 
above (see also “Materials and Methods”). Values represent means ± SEM of three independent 
experiments performed in triplicate. * p<0.05 versus MOPr alone (control) was calculated by 
one-way ANOVA followed by Bonferroni test.  
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ARF6 or PD-ARF6 mutants, but not by co-expression of the DN-ARF1 mutant (Figure 3.11.). On 
the other hand, co-expression of FC-ARF6 mutant together with MOPr and PLD2 increased 
PLD2 activation after morphine treatment almost 2-fold over the control levels, as expected. 
Altogether, our results demonstrated that opioid-induced PLD2 activation is ARF6 mediated and 
PLD assay in cells expressing different ARF6 mutants directly implicated ARF6 protein in this 
process.  
 
3.7. Blocking ARF6 function impairs MOPr recycling  
 
ARF6 protein has been widely implicated in the regulation of plasma 
membrane/endosome trafficking (D’Souza-Schorey and Chavrier, 2006). Therefore we 
investigated next if ARF6 protein also plays a role in trafficking of internalized MOPr to the 
plasma membrane and thus is involved in regulation of receptor recycling. T7-MOPr expressing 
HEK293 cells were transfected with negative ARF6 mutants, DN- and PD-ARF6, or with active 
FC-ARF6 mutant. After 30 min of DAMGO treatment, agonist was removed and the cells were 
treated with the MOPr antagonist 1 µM naloxone for further 30 min to avoid residual DAMGO-
stimulated endocytosis and to keep recycled receptor in the plasma membrane. As shown in 
Figure 3.12.a, the coexpression of FC-ARF6 mutant only slightly increased the amount of 
recycled MOPr, indicating that ARF6 protein activation is not the rate-limiting step in this 
process. However, recycling was strongly decreased after blocking ARF6 function with both DN- 
and PD-ARF6 mutant expression (Figure 3.12.a). Similar reduction of the amount of recycled 
receptor after DAMGO removal was detected after overnight incubation of MOPr expressing 
cells with a myristoylated synthetic peptide N-myr-ARF6, a blocker of PLD activity and a very 
potent inhibitor of DAMGO-induced MOPr endocytosis as well (see Figure 3.12.a). These results 
show that ARF6 protein also regulates MOPr recycling. 
In order to retest our data, these findings were confirmed after knocking down the 
expression of endogenous ARF6 protein using siRNA technology (Figure 3.12.b). ARF6 specific 
siRNA significantly impaired MOPr recycling already in very low concentration (c=150 pM), 
suggesting that trafficking of internalized receptor back to the plasma membrane is very sensitive 
to proper ARF6 function. As expected, ARF1 siRNA as well as non-specific siRNA control had 
no significant effects on the amount of recycled receptor (Figure 3.12.b). Altogether, these results 
implicate both ARF6 and PLD2 proteins in the regulation of MOPr recycling. Together with 
previous data mentioned above, our experiments suggest that ARF6 protein has an important role 
in regulation of MOPr trafficking both from and back to the plasma membrane and this function 
is mediated via modulating PLD2 activity. 
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Figure 3.12. Reduction of MOPr recycling rate by blocking ARF6 function. Control HEK293 
cells stably expressing T7-tagged MOPr alone were transfected or not with a) HA-tagged ARF6 
mutants (FC-ARF6, DN-ARF6 and PD-ARF6) or b) 150 pM indicated siRNAs. In experiment 
with N-myr-ARF6, the cells were kept overnight in DMEM medium supplemented with 25 µM 
peptide prior to experiment. 48 h after transfection, the receptor was surface labeled with T7-
antibody and the cells were stimulated for 30 min with 1 µM DAMGO at 37ºC. Agonist was then 
removed and the cells were incubated at 37ºC for further 30 min with 1 µM naloxone. After 
fixation, the amount of endocytosed receptors was determined by quantitative ELISA as 
described in “Materials and Methods”. The recycling rate was estimated as a percentage of 
recovered surface receptors to endocytosed receptors. Data are presented as means ± SEM of 3-4 
independent experiments performed in triplicate. * p<0.05, ** p<0.01, *** p<0.001 versus MOPr 
alone (control) was calculated by one-way ANOVA followed by Bonferroni test.  
       
 
3.8. ARF6 influences agonist-induced MOPr desensitization 
 
 Presented data clearly demonstrate that ARF6 small GTPase regulates agonist-induced 
MOPr endocytosis as well as receptor recycling via regulating the activity of PLD2 enzyme. 
Since receptor trafficking strongly influences agonist-induced receptor desensitization, it was 
reasonable to assume that ARF6 protein will also affect the rate of MOPr desensitization. To test 
this, we treated the control HEK293 cells expressing MOPr alone and cells co-expressing MOPr 
and either PD-ARF6 or FC-ARF6 mutant with receptor internalizing agonist DAMGO or 
noninternalizing agonist morphine for 2 h (Figure 3.13.). Receptor desensitization was measured 
as the decreased ability of the agonist to inhibit forskolin-stimulated adenylate cyclase activity 
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after extended agonist pretreatment as described in “Materials and Methods” section. Figure 
3.13.a shows that 2 h exposure of receptor to internalizing agonist DAMGO led to receptor 
desensitization of about 25% in control cells. However, after overexpression of PD-ARF6 mutant, 
which is defective in PLD2 activation, the DAMGO-induced receptor desensitization was 
drastically increased (>50%). These results are in line with our previous findings showing that 
inhibition of PLD2 leads to decreased receptor internalization and reactivation and therefore to a 
stronger MOPr desensitization (Koch et al., 2004).  
 
 
 
Figure 3.13. Effects of expression of ARF6 mutants on agonist-induced MOPr 
desensitization. HEK293 cells expressing MOPr with and without coexpression of indicated 
ARF6 mutants were treated with 1 µM DAMGO or 1 µM morphine for 2 h. After washing, the 
cells were treated with forskolin or combination of forskolin and previously used agonist for 
another 15 min and cAMP levels were determined as described under “Materials and Methods”. 
Receptor desensitization was measured as the decreased ability of the agonist to inhibit forskolin-
stimulated adenylate cyclase activity after extended agonist pretreatment. Values represent mean 
± S.E.M. of 3-4 independent measurements performed in duplicate. * p<0.05, ** p<0.01 
compared with control cells expressing MOPr alone (one-way ANOVA followed by Bonferroni 
test).  
 
Furthermore, as Figure 3.13.b shows, co-expression of active FC-ARF6 mutant with 
MOPr did not influence DAMGO-induced receptor desensitization significantly, since PLD2 is 
already activated by DAMGO treatment as we have shown in this study (see Figure 3.11.) and 
previous studies (Koch et al., 2003, 2006). However, morphine can not induce receptor 
endocytosis/recycling and therefore leads to a stronger receptor desensitization compared to the 
internalizing agonist DAMGO (Figure 3.13.a,b). Since morphine can not activate PLD2 (Koch et 
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al., 2003, 2006), blocking the activity of this enzyme by PD-ARF6 mutant expression does not 
influence morphine-induced receptor desensitization. However, after PLD2 activation by FC-
ARF6 mutant, receptor internalization, reactivation and recycling after morphine treatment are 
enhanced and MOPr desensitization is decreased compared to control cells (Figure 3.13.b). 
Therefore, by influencing PLD2-mediated processes like receptor endocytosis and 
reactivation/recycling, ARF6 protein modulates agonist-induced MOPr desensitization as well. 
Altogether, our findings indicate that ARF6 protein via PLD2 activation plays an important role 
in regulation of MOPr trafficking and signaling, processes implicated in tolerance and 
dependence to opioid drugs. 
 
3.9. Desensitization of endogenous MOPr in primary cultured neurons 
 
Since MOPr and PLD2 are endogenously expressed in many brain regions including 
cerebral cortex (Choi et al., 2004; Liao et al., 2005; Mansour et al., 1995; Taki et al., 2000), we 
investigated next whether the DAMGO-induced MOPr desensitization is affected by the 
inhibition of PLD2 activity in cultured primary cortical neurons. For this experiment neuronal 
cultures were prepared from rat cortex of E17 Sprague Dawley rat embryos as described under 
"Materials and Methods" section. To inhibit the function of endogenously expressed PLD2, 
catalytically inactive PLD2 mutant (nPLD2) which has the point mutation K758R was used. Two 
days after transfection with nPLD2, cortical cells were treated with 1 µM DAMGO (up to 2 h) 
and receptor desenzitization was measured as described above. Compared to untransfected 
control cells, nPLD2 expressing cortical neurons exhibited a significantly increased receptor 
desensitization after both 1 h and 2 h of DAMGO pretreatment (Figure 3.14.). This might be due 
to the impaired receptor endocytosis and recycling/reactivation of the MOPr after blocking 
endogenous PLD2 activity. These findings confirm the important regulatory role of PLD2 
identified in our HEK293 cellular model system in the endocytosis and desensitization of the 
endogenously expressed MOPr in neuronal cells.  
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Figure 3.14.  Desensitization of the MOP receptor in cultured primary cortical neurons. 
Newly prepared primary cortical cells (E17) were either kept in culture for 6 days (control) or 
transfected with the catalytically inactive (K758R) PLD2 mutant (nPLD2) on day 4 and kept for 
two additional days in culture before agonist treatment. Then the cells were exposed to 1 µM 
DAMGO for the indicated time periods. After washing, the cells were treated with 5 µM forskolin 
or forskolin plus DAMGO for 15 min, and cAMP levels were determined as described under 
“Materials and Methods”. The maximum inhibition of intracellular cAMP accumulation in cells 
without agonist pretreatment was defined as 100%. Values represent mean ± SEM of 3-4 
independent measurements performed in duplicate. *p0.01 compared with the desensitization of 
the control cells (Student‟s t test). 
 
 
 
3.10. Role of ARF6 GDP/GTP cycle in MOPr endocytosis/recycling 
 
 Presented results demonstrate that ARF6 protein plays an important role in regulation of 
MOPr endocytosis, desensitization/signaling and recycling. Moreover, our data show that these 
effects of ARF6 are mediated via PLD2, a phospholipid modifying enzyme that has a crucial role 
in these processes as we have shown previously (Koch et al., 2003, 2004, 2006).  
As already mentioned, ARF6 cycles between its GTP-bound and its GDP-bound states 
like other small G proteins, and these states are considered to represent ARF6 active and inactive 
conformation, respectively. Due to the reasons mentioned before (see Chapter 1.4.2.), the “fast 
cycling” ARF6/T157N mutant was used in our previous work to investigate the effects of active 
ARF6 mutant overexpression of MOPr endocytosis (see Chapter 3.4.). However, we wanted to 
investigate next how important is a full GDP/GTP cycle for ARF6 regulation of MOPr 
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endocytosis and recycling. To do this, first we tested and compared the following ARF6 active 
mutants in both MOPr endocytosis and recycling experiments: 
a) "GTP-locked" ARF6/Q67L mutant (GTP-ARF6) that can not hydrolyze GTP and 
b) "fast cycling" ARF6/T157N mutant (FC-ARF6) that can undergo spontaneous 
GDP/GTP exchange. 
HEK293 cells stably expressing T7-tagged MOPr were transiently transfected with HA-
tagged GTP-ARF6 or FC-ARF6 mutant. For endocytosis measurements, 48 h after transfection 
the receptor was specifically surface labeled with T7-antibody and then the cells were treated or 
not with 1 µM receptor internalizing agonist DAMGO for 30 min at 37ºC. After agonist 
treatment, the cells were fixed and the amount of internalized receptor was quantified by ELISA 
as described. As Figure 3.15.a shows, both mutants had no significant effects on DAMGO-
induced MOPr endocytosis. We detected ~25% of agonist-induced receptor internalization in 
both control cells expressing MOPr alone and cells coexpressing MOPr and GTP-ARF6 or FC-
ARF6 mutant. This result suggests that both ARF6 active mutants act similarly in the cells and 
GTP hydrolysis seems not to be a crucial step for ARF6 function in the regulation of MOPr 
endocytosis.  
 Next we tested receptor recycling using the same cellular model system and 
methodological approach. In these experiments, after 30 min of 1 µM DAMGO stimulation the 
agonist was removed and after washing the cells were treated for further 30 min with 1 µM 
naloxone before fixation. As mentioned before, this MOPr antagonist was used in order to avoid 
residual DAMGO-stimulated endocytosis and to keep recycled receptor in the plasma membrane. 
Figure 3.15.b shows that expression of FC-ARF6 mutant did not influence receptor trafficking to 
the plasma membrane significantly. After 30 min agonist washout, ~60% of receptor was 
recycled in both control cells expressing MOPr alone and cells co-expressing MOPr and FC-
ARF6 mutant. Surprisingly, expression of GTP-ARF6 mutant strongly decreased the amount of 
recycled MOPr for ~50% (from ~60% to ~30%, Figure 3.15.b). A similar level of reduction of 
MOPr recycling was detected after expression of dominant negative ARF6 mutant DN-ARF6 (see 
Figure 3.12.a for comparison), suggesting that GTP-ARF6 mutant, although active, exhibits a 
negative phenotype in MOPr recycling assays. This is in line with previous studies that have 
reported that GTP-ARF6 mutant acts similarly like dominant negative mutant in some 
experiments, showing negative effects although it is regarded to be constitutively active 
(D'Souza-Schorey et al., 1995; Radhakrishna and Donaldson, 1997; Altschuler et al., 1999; 
Claing et al., 2001; Hashimoto et al., 2004). Therefore, GTP hydrolysis and ARF6 inactivation 
seem to be an essential step for proper function of ARF6 in MOPr trafficking back to the plasma 
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membrane. Moreover, in our experiments HEK293 cells transfected with GTP-ARF6 mutant got 
round-shaped, detached from the dish and had decreased survival rate after transfection in 
comparison to the cells transfected with FC-ARF6 mutant.  These findings are also in line with 
the previous reports showing that locking ARF6 in its GTP-bound form alters cell morphology 
and impairs cell viability (Brown et al., 2001; D'Souza-Schorey et al., 1998; Peters et al., 1995). 
             
Figure 3.15. Quantitative analysis of MOPr endocytosis and recycling in HEK293 cells co-
transfected with MOPr and FC-ARF6 or GTP-ARF6 mutant. Control HEK293 cells stably 
expressing T7-tagged MOPr alone or cells coexpressing T7-tagged MOPr and indicated HA-
tagged ARF6 mutants were incubated for 1,5 h at 4ºC with T7-antibody to label surface receptors. 
For endocytosis quantification (Fig. 3.15.a), the cells were treated with 1µM DAMGO for 30 min 
at 37ºC to induce receptor internalization and then fixed. In recycling experiments (Fig. 3.15.b), 
after DAMGO stimulation the agonist was washed away and the cells were treated with 1µM 
naloxone for further 30 min as described under “Materials and Methods”. Receptor 
internalization was quantified as the percent loss of cell surface receptors. The recycling rate was 
estimated as a percentage of recovered surface receptors to endocytosed receptors. Data are 
presented as means ± SEM of three independent experiments performed in triplicate. * p<0.05 
versus MOPr alone (control) was calculated by one-way ANOVA followed by Bonferroni test.  
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3.11. “GTP-locked” ARF6 mutant (GTP-ARF6) induces formation of the actin-rich 
vacuolar structures  
 
 In the previous section we demonstrated that overexpression of GTP-ARF6 mutant 
impairs MOPr recycling but not receptor endocytosis. Therefore we looked next what could be 
the mechanism of the observed effects. It has been previously reported that expression of GTP-
ARF6 induces formation of a large vacuolar clusters in the cells that are rich in actin and PIP2 
(D'Souza-Schorey et al., 1995; Brown et al., 2001; Radhakrishna and Donaldson 1997). Since 
these structures are endosomally derived, it can be suggested that they might be implicated in 
MOPr trafficking and connected with decreased recycling rate that we detected in the cells 
expressing GTP-ARF6 mutant. 
 Thus, we first investigated the effect of expression of GTP-ARF6 mutant on the actin 
cytoskeleton in HEK293 cells. For these experiments, commercially available rhodamine-
phalloidin was used (see “Materials and Methods”). This fluorescently labeled phallotoxin is 
isolated from Amanita phalloides mushroom and specifically binds to and stabilizes F-actin. 
Rhodamine-phalloidin staining revealed that HEK293 cells transfected with GTP-ARF6 mutant 
got round-shaped, as noticed before, and indeed developed actin-rich structures (Figure 3.16.a). 
However, due to dramatic morphological changes of HEK293 cells transfected with GTP-ARF6 
mutant, these cells were very hard to image under the microscope and therefore we decided to use 
COS-7 cell line for further experiments. These cells are bigger and more flat than HEK293 cells 
and in the literature represent more commonly used cell model system for investigation of actin 
cytoskeleton rearrangements. It could be seen that COS-7 cells transfected with GTP-ARF6 
mutant lost most of the actin stress fibers that are present throughout the control (untransfected) 
cells and clearly developed actin-rich accumulations, similar to those seen in transfected HEK293 
cells (Figure 3.16.b). Figure 3.16.c shows a closer look to these structures revealing that these are 
indeed clusters of vacuoles with strong actin staining in the membrane. These structures were 
formed approximately 8-10 hours after transfection, consistently with the time of GTP-ARF6 
expression (data not shown) and by their existence the transfected cells could be clearly identified 
under the microscope. On the other hand, in COS-7 cells transfected with FC-ARF6 mutant no 
vacuolar structures were detected (Figure 3.16.b, lower panels). These results show that 
generation of vacuolar structures enriched in actin molecules in our experiments is not an artifact 
of cell transfection and is specificaly due to the expression of “GTP-locked” ARF6 mutant. 
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See Figure legend on the next page. 
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Figure 3.16. Overexpression of GTP-ARF6 mutant induces formation of actin-rich vacuolar 
structures. HEK293 cells (Fig. 3.16.a) or COS-7 cells (Fig. 3.16.b) were transfected or not 
(control) with indicated ARF6 mutants (HA-ARF immunostaining is shown in green). 48 h after 
transfection, the cells were stained for F-actin using rhodamine-phalloidin (shown in red) as 
described under “Materials and Methods”. Note the loss of actin stress fibers and formation of 
actin-rich clusters of vesicles in cells transfected with GTP-ARF6 mutant. FC-ARF6 mutant 
induced no dramatic changes of actin cytoskeleton or cluster formation (Fig. 3.16.b, lower 
panels). c) Closer look to actin-rich cluster of vesicles in COS-7 cell transfected with GTP-ARF6 
mutant. 
 
 
 
3.12. Endocytosed MOPr gets “trapped” in actin-rich vacuolar compartment induced 
by GTP-ARF6 mutant overexpression in COS-7 cells 
 
Next we investigated how MOPr trafficking in COS-7 cells is affected by transfection 
with GTP-ARF6 mutant. Since in the literature COS-7 cells are not commonly used as a cell 
model system for investigation of receptor trafficking, we made some preliminary tests first in 
order to be sure that MOPr expressed in COS-7 cells follows the same endocytosis and recycling 
pattern like in HEK293 cellular model or neuronal cells.  MOPr belongs to a group of G protein-
coupled receptors that are endocytosed via clathrin-coated pits and inside the cells it can be found 
colocalized with transferrin receptor (TfR) which is used as a marker for clathrin-dependent 
endocytosis. In COS-7 cells transfected with HA-MOPr, we could also detect extensive 
colocalization of internalized HA-tagged MOPr with TfR (Figure 3.17.) demonstrating clathrin-
dependent route of MOPr internalization in this cell model. Following MOPr internalization and 
sorting, most of the receptors are recycled back to the plasma membrane in reactivated form and 
significant downregulation of receptor is not detected after short agonist treatment. Indeed, as 
shown on the Figure 3.18., MOPr is almost completely recycled back to the plasma membrane of 
control COS-7 cells expressing MOPr alone in recycling experiments (30 min of 1 µM DAMGO-
induced internalization, agonist washout and 30 min of treatment with 1 µM receptor antagonist 
naloxone). Moreover, the residual vesicles that can be seen in the cells are positive for Rab11, a 
small GTPase that is a marker for recycling endosomes (Fig. 3.18.a, blue immunostaining). These 
results confirmed that trafficking behaviour of MOPr expressed in COS-7 cells resembles 
trafficking in other cell model systems including neuronal cells which are physiological 
environment for opioid receptors.  
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Figure 3.17. Colocalization of internalized HA-MOPr and transferrin receptor (TfR) 
demonstrates clathrin-dependent endocytosis of MOPr in transfected COS-7 cells. COS-7 
cells were transfected with HA-MOPr and 48 h after transfection "pulse-chase" assay was done as 
described in "Materials and Methods" section. Note massive colocalization of internalized MOPr 
receptor and TfR receptor which is used as a marker for clathrin-dependent endocytosis.  
 
 
 
Then we investigated how expression of “GTP-locked” ARF6 mutant influences the 
recycling of internalized MOPr. It can be seen on Figure 3.19. that situation is dramatically 
different in cells transfected with this mutant which could be clearly identified by formation of 
actin-rich clusters. Namely, most of the receptor stayed inside the transfected cells after agonist 
washout and during recycling, and strikingly, colocalized extensively with actin-rich structures 
induced by the expression of GTP-ARF6 mutant. Moreover, Figure 3.19. shows an adjacent cell 
that is transfected with HA-MOPr but not with GTP-ARF6 mutant and has no enlarged 
endosomes or changes in actin cytoskeleton. It can be seen that this cell shows similar pattern of 
MOPr recycling like control cells transfected only with MOPr (see Figure 3.18. for comparison).  
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Figure 3.18. Trafficking of HA-MOPr in transfected COS-7 cells. COS-7 cells were 
transfected with HA-MOPr as described in "Materials and Methods". 48 h after transfection, the 
cells were  (a) treated with 1 µM DAMGO for 30 min to induce receptor endocytosis or (b) after 
30 min of treatment with 1 µM DAMGO the agonist was washed away and the cells were treated 
for another 30 min with1 µM receptor antagonist naloxone (receptor recycling). Note that the 
most of receptor is internalized after DAMGO treatment (a) and could be seen in endocytotic 
vesicles inside the COS-7 cells. Moreover, internalized MOPr recycled almost completely to the 
plasma membrane after 30 min DAMGO-free interval (recycling) (b). 
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These experiments show that when GTP hydrolysis of ARF6 protein is blocked by GTP-ARF6 
mutant overexpression, endocytosed MOPr seems to get “trapped” in actin-rich vacuolar 
structures that are formed in the cells and can not recycle back to the plasma membrane. This is in 
correlation with our quantitative data from HEK293 cells (Fig. 3.15.b) that show a decrease in 
MOPr recycling after overexpression of GTP-ARF6 mutant. Therefore, these results suggest that 
GTPase activity and full cycle of GTP/GDP exchange of ARF6 protein are important for the 
trafficking of endocytosed MOPr back to the plasma membrane during receptor recycling. 
 
 
 
 
Figure 3.19. Recycling of internalized HA-MOPr is blocked in COS-7 cells transfected with 
GTP-ARF6 mutant. COS-7 cells were co-transfected with HA-MOPr and GTP-ARF6 mutant as 
described in "Materials and Methods". 48 h after transfection, the cells were first treated with 1 
µM DAMGO for 30 min to induce receptor endocytosis and then the agonist was washed away 
and the cells were treated for another 30 min with1 µM receptor antagonist naloxone (receptor 
recycling). Note that in the cells that are co-transfected with HA-MOPr and GTP-ARF6 mutant 
(in which actin-rich structures are formed) the most of internalized receptor stayed inside the cells 
and extensively colocalized with actin-rich clusters of vesicles. Moreover, in adjacent control cell 
that is transfected only with MOPr, internalized receptor recycled almost completely to the 
plasma membrane after 30 min DAMGO-free interval. 
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4. Discussion 
 
 
 The investigation of molecular mechanisms regulating endocytosis of MOPr is of clinical 
importance because MOPr endocytosis counteracts the development of tolerance to opioid drugs 
by facilitating the reactivation of desensitized receptors (Koch et al., 2005). Therefore, the present 
study investigated the role of two molecular players involved in regulation of MOPr trafficking 
and signaling, namely PLD2 and ARF proteins.  
In the first part of the present study, reported data demonstrate that opioid-induced PLD2 
activation and subsequent receptor endocytosis is mediated via ARF6 and not ARF1 protein. This 
conclusion is based on the following observations: 1) dominant negative mutants or siRNA knock 
down of ARF6 but not of ARF1 inhibit agonist-induced MOPr endocytosis; 2) active, “fast 
cycling” mutant of ARF6 increases the morphine-induced MOPr endocytosis; 3) blocking PLD2 
activation by the PLD-defective ARF6 mutant inhibits agonist-induced MOPr endocytosis; 4) 
opioid-mediated activation of PLD2 is blocked in the presence of dominant negative or PLD-
deficient ARF6 mutants. Further, we demonstrated that blocking of ARF6 function impairs MOPr 
recycling as well and that ARF6 protein also affects the receptor desensitization/resensitization 
via regulating MOPr trafficking. Second part of this study demonstrates the importance of GTP 
hydrolysis of activated ARF6 protein and full GDP/GTP cycle for the trafficking of internalized 
MOPr back to the plasma membrane since locking ARF6 in its GTP-bound, active state blocks 
recycling of the receptor.  
 
4.1. ARF6 protein regulates MOPr endocytosis via PLD2 activation 
  
PLD is an ubiquitous enzyme that catalyzes the hydrolysis of PC, the major phospholipid 
of membranes, to PA and choline. PA has been implicated to have many different functions in 
signal transduction, vesicle formation, and cytoskeleton dynamics (Liscovitch and Cantley, 1995; 
Liscovitch et al., 1999). There are two mammalian PLD isoforms, PLD1 and PLD2, differing in 
their cellular localization and regulation. PLD1 is located in the cytosol, Golgi apparatus, nucleus 
and plasma membrane, while PLD2 seems to be largely found on the plasma membrane 
(Liscovitch et al., 1999). 
PLDs can be activated by ARFs, Rho, PIP2 and protein kinase C (Liscovitch et al., 2000; 
Exton, 2002; Hiroyama and Exton, 2005). Additionally, PLD activity has been shown to be 
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regulated by a number of GPCRs as mentioned before (see Chapter 1.4.1.). Using a yeast two-
hybrid screening, our group has shown interaction between cytoplasmatic C-terminal part of 
MOPr and N-terminal part of PLD2 (Koch et al., 2003). Moreover, these studies demonstrated 
that PLD2 can be activated via MOPr and that opioid-mediated activation of PLD2 is a key step 
during the induction of agonist-mediated endocytosis and recycling of the receptor affecting the 
development of opioid tolerance (Koch et al., 2003, 2004).  
PLD2 is predominantly activated by ARF family of small GTPases and not by PKC 
(Exton, 2002; Hiroyama and Exton, 2005; Koch et al., 2003). Therefore ARF proteins might be 
involved in regulation of receptor trafficking and signaling via modulating PLD2 activity. As 
mentioned before, both ARF1 and ARF6 members of ARF family of small GTPases seem to be 
promising candidates for this function. This led us to examine whether ARF1 or ARF6 protein is 
involved in the μ-opioid receptor-mediated PLD2 activation and receptor trafficking.  
The data reported here provide evidence that opioid-induced PLD2 activation and 
subsequent receptor endocytosis is mediated via ARF6 and not ARF1 protein. This conclusion is 
based on several experiments. First, overexpression of dominant negative ARF6 and not ARF1 
mutant induced significant decrease in DAMGO-mediated MOPr endocytosis in HEK293 cell 
model system (Figure 3.1. and 3.2.) as well as transfected cortical neurons (Figure 3.5.). 
Moreover, knocking down of endogenous ARF6 protein expression in HEK293 cells by siRNA 
technology gave similar results (Figure 3.3. and 3.4.). On the other hand, overexpression of active 
“fast cycling” ARF6 mutant significantly increased MOPr endocytosis in both cellular systems 
used after treatment with morphine, an agonist that does not induce receptor endocytosis itself 
(Figure 3.6. and 3.7.). Finally, several lines of evidence show that ARF6 protein has a role in 
opioid-mediated PLD2 activation which is essential for MOPr internalization. Namely, 
overexpression of mutant which is selectively incapable of activating PLD decreases MOPr 
endocytosis and this block can be bypassed by heterologous activation of PLD2 via PKC pathway 
using PMA treatment (Figure 3.8.). Moreover, direct measurement of PLD activity using 
transphosphatidylation reaction showed that DAMGO-induced PLD2 activity is decreased in the 
presence of negative ARF6 mutants while activating ARF6 by “fast cycling” ARF6 mutant 
overexpression increases PLD2 activation after morphine treatment, as expected (Figure 3.11.).  
Altogether, these findings are in agreement with other publications showing that ARF6 
protein can activate PLD2 in vivo (Hiroyama and Exton, 2005), that ARF6 mediates the 
somatostatin-induced PLD-activity (Grodnitzky et al., 2007) and that ARNO, a guanine 
nucleotide exchange factor for ARF6, can increase PLD activity (Santy and Casanova, 2001). In 
addition, our results are consistent with previous findings demonstrating that ARF6 and not 
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ARF1 regulates the internalization of other GPCRs, such as ß2-adrenergic receptor, endothelin 
receptor and m2 muscarinic receptor (Claing et al., 2001; Houndolo et al., 2005). In summary, 
several studies indicate that ARF6 can increase PLD activity and GPCR endocytosis in vivo and 
the present findings point to PLD2 as the target of ARF6 in vivo.  
It is interesting to mention that ARF6 seems to have a role in receptor internalization 
through multiple endocytic pathways. Namely, knock down of ARF6 protein expression using 
siRNAs revealed that ARF6 regulates the internalization of most GPCRs, irrespective of 
receptor‟s route of entry (Houndolo et al., 2005). As such, receptors internalized through the 
clathrin, the caveolae, and the clathrin- and caveolae-independent pathway require ARF6 activity. 
Moreover, it has been shown that activation of ARF protein occurs upon agonist activation of a 
number of different GPCRs, including the β2-adrenergic, m3 muscarinic acetylcholine, fMet-Leu-
Phe, H1 histamine, gonadotropin releasing hormone, and B2 bradykinin receptors (Bornancin et 
al., 1993; Rümenapp et al., 1995; Houle at al., 1995; Mitchell et al., 1998). Therefore the 
investigation of whether treatment of cells expressing MOPr with opioid agonists also induces 
ARF6 activation and determination if there is a difference between internalizing and 
noninternalizing MOPr agonists regarding this ability gives space for further research. Since we 
have shown previously that there is a correlation between the ability of agonist to induce receptor 
endocytosis and to activate PLD2, it would be interesting to see if there is a parallel between 
these findings and the ability of agonists to activate ARF6.  
According to a model, activated ARF6 would then have the effect on phospholipid 
metabolism by activating PLD as well as type I PIP5K (Honda et al., 1999; Krauss et al., 2003). 
PA, the product of PLD activity, could change the physical (e.g. charge, pH) and chemical 
properties of the plasma membrane in order to facilitate vesicle budding and in turn functions as a 
cofactor in the activation of PIP5K (Martin, 2001). Therefore it is possible that synergistic effect 
of ARF6 on PIP5K as well as on PLD activity can lead to a large increases in PIP2 at the cell 
periphery which has been shown to have a role in regulation of clathrin-dependent endocytosis 
(Wenk and De Camilli, 2004). Indeed, ARF6 binds to and activates PIP5KIγ, leading to the 
recruitment of clathrin coats in synaptic vesicle preparations (Krauss et al., 2003). Moreover, 
ARF6-GTP and PIP2 function synergistically to recruit AP-2 onto liposomes as well, pointing 
towards the role of ARF6 in coated pit assembly (Paleotti et al., 2005). Therefore, the mentioned 
scenario gives a broader view on the role that ARF6 and opioid-mediated PLD2 activation might 
have in clathrin-dependent internalization of MOPr.  
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4.2. Recycling of endocytosed MOPr is regulated via ARF6 protein 
 
Further, we demonstrated that blocking ARF6 function impairs MOPr recycling. This 
conclusion was drown out from experiments showing that overexpression of ARF6 negative 
mutants as well as siRNA-mediated knock down of endogenous ARF6 protein expression in 
HEK293 cells stably expressing HA-MOPr significantly decreased the amount of recycled MOPr 
receptor after agonist washout (Figure 3.12.). A requirement for ARF6 in endosome recycling 
was first documented in Chinese Hamster Ovary (CHO) cells, in which the expression of a 
dominant negative ARF6 mutant blocked the recycling of endosomal ligands (D'Souza-Schorey et 
al., 1998). Furthermore, EFA6, a guanine nucleotide exchange factor for ARF6, regulates 
constitutive endosomal recycling to the cell surface through a PLD2-dependent pathway (Padron 
et al., 2006). In addition, in the absence of PLD2, the transferrin receptors are mistargeted to the 
slow recycling pathway (Padron et al., 2006). These findings are consistent with a proposed 
functional role of ARF6 in the endosomal sorting processes (Naslavsky et al., 2003; 2004). In 
fact, there is compelling evidence that ARF6-regulated delivery and insertion of recycling 
endosomal membranes at the cell surface requires PLD activity (Padron et al., 2006; Jovanovic et 
al., 2006) and is mediated by the vesicle-tethering exocyst complex (Prigent et al., 2003). It has 
been demonstrated that ARF6 interacts with sec10, a subunit of the exocyst complex that 
localizes to the recycling endosomes and is redistributed to the cell surface after ARF6 activation. 
ARF6 bound to sec10 might activate PLD2, producing PA and subsequently increase the PIP2 
level on vesicles during tethering. We also previously observed that blocking of PLD2-mediated 
PA synthesis impairs not only the endocytosis but also the recycling/resensitization of MOPr 
(Koch et al., 2004), indicating the important role of PA in the regulation of endosomal trafficking. 
Interestingly, in the literature ARF6 protein has been mostly implicated in the recycling 
of proteins that are internalized via clathrin-independent pathway. These molecules are integral 
plasma membrane proteins that lack cytoplasmic AP-2 and clathrin-sorting sequences, including 
the IL2 receptor α subunit, MHC class I, and glycosylphosphatidylinositol (GPI)-anchored 
proteins (Naslavsky et al., 2003; Radhakrishna and Donaldson, 1997). ARF6-labelled recycling 
tubules in these cells exhibit minimal overlap with early endosomes and radiate from the 
juxtanuclear cell region to the cell periphery. However, there are studies showing that the traffic 
of plasma membrane proteins that either lack the clathrin-dependent sorting signals or that are 
mediated by classic clathrin-dependent pathway converge in common recycling endosomes 
(Naslavsky et al., 2003). Indeed, internalized β1 integrin in HeLa cells that recycles to the surface 
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in an ARF6-dependent manner colocalizes with internalized transferrin (marker for clathrin-
dependent endocytosis and early endosome compartment), the small GTPase Rab11 (marker for 
recycling endosome) and MHC class I molecules in recycling endosomes (Powelka et al., 2004). 
Together with necessity for PLD2 activity in recycling which has been shown previously and 
mentioned above, these facts might explain the role of ARF6 in regulation of MOPr recycling 
since this receptor is internalized via clathrin-dependent pathway. Moreover, in the second part of 
this study we have shown the necessity for GTP hydrolysis of active ARF6-GTP for proper 
MOPr recycling to the plasma membrane which is discussed below (see Chapter 4.4.). 
 
4.3. ARF6 protein has influence on MOPr desensitization 
 
It is well known that peptide agonists, such as DAMGO, and many opioid alkaloids 
induce rapid endocytosis of MOPr in a number of cell types. By contrast, the alkaloid drug 
morphine is weak in promoting receptor internalization. Since receptor trafficking (endocytosis 
and recycling) is an important regulator of agonist-induced receptor desensitization, the 
significant differences in DAMGO- and morphine-mediated receptor trafficking should lead to 
differences in receptor desensitization as well. In our study, Figure 3.13. shows that 2 h treatment 
with morphine leads to significant MOPr desensitization which occurs at a much higher rate 
compared with that after 2 h DAMGO treatment. Numerous studies have demonstrated that 
agonist-induced GPCR endocytosis contributes to functional resensitization of signal transduction 
by promoting dephosphorylation and recycling of reactivated receptors to the plasma membrane 
(Ferguson and Caron, 1998; Lefkowitz,1998; Koch et al., 1998, 2005; Schulz et al., 2004). 
Therefore, the explanation for the differences in DAMGO- and morphine-induced desensitization 
could be the inability of morphine to induce PLD2 activation, MOPr internalization and recycling 
which lead to receptor resensitization. 
In support of this receptor recycling theory, it has been demonstrated that the endocytotic 
efficacies of various opioid drugs are negatively correlated with their ability to cause receptor 
desensitization in HEK293 cells (Koch et al., 2005) and that opioid drugs with high endocytotic 
efficacies induced less opioid tolerance than non-internalizing agonists in rats (Grecksch et al., 
2006). Thus, blocking ARF6-mediated MOPr endocytosis and recycling should also affect the 
receptor desensitization/resensitization. In fact, blocking ARF6-mediated PLD2 activation 
resulted in a significantly higher MOPr desensitization after treatment with the internalizing 
agonist DAMGO (Figure 3.13.). On the other hand, overexpression of an active ARF6 mutant 
facilitates MOPr endocytosis/recycling and reduces the MOPr desensitization after treatment with 
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the agonist morphine, which is normally incapable of activating PLD2 and thus does not induce 
MOPr endocytosis (Figure 3.13.). These findings support the hypothesis that MOPr endocytosis 
counteracts the development of opioid receptor desensitization and tolerance (Koch et al., 2005). 
Furthermore, they are in line with previous studies from our group demonstrating that PLD2 
activity is important for the regulation of MOPr desensitization and resensitization in HEK293 
cells stably expressing MOPr (Koch et al., 2004). In the presented work, we also reconfirmed 
these results in cultured cortical neuronal cells endogenously expressing MOPr by showing that 
expression of catalytically inactive (K758R) PLD2 mutant (nPLD2) increased receptor 
desensitization after both 1 h and 2 h of DAMGO pretreatment, as expected (Figure 3.14.). 
Together with other data from neuronal cells , these experiments were done in order to assure that 
effects that we see are not an artifact of HEK293 cell model system and that the main components 
and mechanisms identified in transfected HEK293 cells are closely related to those seen in more 
physiological context, i.e. in neuronal cells. Therefore we can suggest that an ARF6-mediated 
PLD2 activation after opioid treatment might play a role in development of tolerance and 
dependence to opioid drugs, adaptive changes in the brain that greatly limit the therapeutic use of 
opioids.  
 
4.4. GTP hydrolysis of ARF6 is necessary for efficient MOPr recycling  
 
 Like other small G proteins, ARF6 cycles between its GTP-bound and GDP-bound states, 
which are considered to represent ARF6 active and inactive conformation, respectively. This 
implies that a GTPase-defective mutant locked in a GTP-bound form would reproduce the 
functions controlled by activated ARF6. However, it has long been appreciated for many G 
proteins that GTP hydrolysis as well is necessary to elicit the full biological response, suggesting 
that the completion of the full GTP/GDP cycle is important (reviewed in Klein et al., 2006). 
Therefore, it appears that, in many cases, to recapitulate the biological functions of small G 
proteins, mutants that cycle between their GTP- and GDP-bound forms, so called “fast cycling” 
mutants, are more representative of the small G protein natural activities.  
In the same study by Klein and colleagues (Klein et al., 2006), the authors compared “fast 
cycling” ARF6 mutant (ARF6/T157N) and classical “GTP-locked” ARF6 mutant (ARF6/Q67L) 
and established the necessity for completion of the ARF6 GTP/GDP cycle for recycling of MHC 
class I molecules to the plasma membrane. Moreover, ARF6/Q67L mutant has been previously 
shown to block the recycling of non-clasically internalized receptors (Radhakrishna and 
Donaldson, 1997; Naslavsky et al., 2003). Namely, after expression of this mutant, internalized 
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molecules accumulated in an intracellular compartment caused by a block in fusion of the 
endocytic vesicles with the classical early endosome compartment (Klein et al., 2006; Naslavsky 
et al., 2003). On the other hand, “fast cycling” ARF6/T157N mutant did not block recycling of 
the receptors suggesting that ARF6-GTP inactivation, i.e. catalytic activity of certain ARF6 GAP 
protein(s) is necessary for the proper recycling of MHC class I molecules to the plasma 
membrane (Klein et al., 2006). 
 By using “fast cycling” ARF6 mutant and classical “GTP-locked” ARF6 mutant (GTP-
ARF6), we also tested how important is full GTP/GDP cycle for ARF6 regulation of MOPr 
endocytosis and recycling. Our results show that both mutants act similarly in the endocytosis 
assay, but, however, in recycling assay only the GTP-ARF6 mutant was strongly inhibitory 
(Figure 3.15.). This is in line with the mentioned study (Klein et al., 2006) and demonstrates that 
GTP hydrolysis of activated ARF6-GTP seems to be a necessary step for recycling of MOPr as 
well. However, it is interesting to mention that previous studies mostly implicated ARF6 in 
regulation of endocytosis and recycling of receptors that are internalized via clathrin-independent 
pathways, which is not the case for MOPr. In fact, a novel plasma membrane recycling pathway 
regulated by ARF6 has been described (Radhakrishna and Donaldson, 1997) which is distinct 
from transferrin-positive endosomes. However, MOPr belongs to a group of GPCRs that are 
internalized via clathrin-coated pits, as demonstrated in COS-7 cell model system by 
colocalization of endocytosed MOPr with transferrin receptor which is used as a marker for 
clathrin-dependent endocytosis (Figure 3.17.). Therefore our data from these experiments 
together with data showing a block of MOPr recycling after overexpression of negative ARF6 
mutants of siRNA knock down of endogenous ARF6 expression suggest that ARF6 might have a 
broader role in cargo trafficking than previously described. 
Further investigation revealed that overexpression of “GTP-locked” ARF6 mutant 
induces dramatic changes in cytoskeleton organization and formation of actin- and PIP2-rich large 
vacuolar clusters in transfected cells (Figure 3.16.). These clusters are enlarged endosomes that 
have been detected in both HEK293 and COS-7 cell model system after transfection with GTP-
ARF6 mutant (Figure 3.16.) and have been described previously (D'Souza-Schorey et al., 1995; 
Brown et al., 2001; Radhakrishna and Donaldson, 1997). However, since expression of GTP-
ARF6 mutant induced dramatic changes of HEK293 cells morphology making a precise 
investigation impossible, the following experiments were done in COS-7 cells as a model system. 
Immunocytochemical analysis of MOPr recycling in COS-7 cells transfected with “GTP-locked” 
ARF6 mutant revealed that internalized MOPr actually gets “trapped” in formed actin-rich 
structures (Figure 3.19.) and is unable to recycle back to the plasma membrane. Obtained results 
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were intriguing since previous work reported similar findings again only for molecules 
internalized by clathrin-independent mechanism (D'Souza-Schorey et al., 1995; Brown et al., 
2001; Radhakrishna and Donaldson 1997).  
But how and why are actin-rich structures formed in cells overexpressing “GTP-locked” 
ARF6 mutant? It is thought that these enlarged endosomes are formed by stimulated homotypic 
fusion of ARF6- and PIP2-containing endosomes (Naslavsky et al., 2003; Brown et al., 2001). 
The authors hypothesized that ARF6-containing early endosome must undergo ARF6 inactivation 
(through GTP hydrolysis) and probably removal or modification of PIP2 before becoming 
competent to acquire early endosomal antigen 1 (EEA1) molecules by heterotypic fusion with 
“classical” early endosome labeled with EEA1, Rab5 and transferrin molecules, all of which are 
used as a markers for this cellular compartment. Interestingly, a similar enlargement of early 
endosomes was previously described for constitutively active Rab5/Q79L mutant also (Stenmark 
et al., 1994). However, the authors in the mentioned study have shown that sequestration of 
internalized cargo into actin-rich vesicles induced by “GTP-locked” ARF6 mutant overexpression 
occurs before fusion with “classical” Rab5-containing early endosome (Naslavsky et al., 2003). 
Moreover, since PLD2 is a downstream effector of activated ARF6, locking ARF6 in its active, 
GTP-bound state migth lead to PLD2 superactivation and extensive production of PA. Further, 
this phospholipid can increase the formation of PIP2 over PIP5K by activating this enzyme. 
Finally, this cascade could promote homotypic fusion and be a possible mechanism of formation 
of observed enlarged endosomes.   
Altogether, we can say regarding this part of the study that additional work is needed in 
order to investigate the observed effects in more details and to characterize the nature of actin-
rich enlarged endosomes induced by GTP-ARF6 mutant overexpression using appropriate 
markers for different cellular compartments. Moreover, more precise analysis and comparison of 
the steps that occur during internalization of MOPr in cells expressing “GTP-locked” ARF6 
mutant should be done. This would clarify in which step from early endosome to recycling 
endosome the trafficking of internalized MOPr is blocked and give us some hints about the 
mechanisms that might be involved.  
Finally, we can generally summarize what is known about the role of small GTPase 
ARF6 in endocytosis by the following cartoon modified from recent review by D'Souza-Schorey 
and Chavrier, 2006 (Figure 4.1.). Through its effect on PIP5K and PLD and the production of 
PIP2, activated ARF6-GTP can facilitate both clathrin-dependent as well as clathrin-independent 
internalization of proteins. ARF6-regulated recruitment of adaptor protein AP-2 and other 
molecules promotes clathrin-dependent endocytosis. Moreover, our previous work as well as this  
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Figure 4.1. The role of ARF6 in clathrin-dependent and clathrin-independent endocytic 
pathways (modified from D'Souza-Schorey and Chavrier, 2006). See text for details. 
 
 
 
study demonstrates that ARF6-mediated PLD2 activation and PA production are a key step in 
agonist-induced internalization of MOPr. On the other hand, ARF6 activation has been also 
linked to the dissociation of arrestin molecules to facilitate receptor internalization (Mukherjee et 
al., 2000; Claing et al., 2001). After internalization of proteins, ARF6-GTP hydrolysis through 
specific GAPs seems to be required for further trafficking along each pathway, whereas the 
activation of ARF6 through specific GEFs promotes the recycling and subsequent fusion of an 
endosomal membranes with the plasma membrane. In this step again activity of PLD has been 
shown to be crucial since ARF6-regulated membrane recycling is mediated in part by the vesicle-
tethering exocyst complex and PLD activation. Therefore our data from the presented study 
showing a role of ARF6 in opioid-mediated PLD2 activation and trafficking of MOPr are in line 
with previous findings and presented scenario. The fuctional interaction and the interplay 
between ARF6, PLD2 and MOPr are required in multiple steps during receptor endocytosis, 
recycling and signaling and are documented in this work. 
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6. Abbreviations 
 
A 
AC - adenylate cyclase 
AP-2 – adaptor protein 2 
APS - ammonium persulfate 
ARF – ADP-ribosylation factor 
ARNO - ADP-ribosylation factor nucleotide-binding site opener 
 
B 
BSA –bovine serum albumin 
 
C 
CamKII - Ca
2+
 - calmodulin dependent protein kinase II 
cAMP - cyclic adenosine monophosphate  
CHO cells- Chinese hamster ovary cells 
COS-7 cells- African green monkey kidney fibroblast cells 
 
D 
DAG - diacylglycerol 
DAMGO - [D-Ala
2
,NMe-Phe
4
,Gly-ol
5
]-enkephalin 
DMEM - Dulbecco‟s Modified Eagle‟s Medium 
DNA - deoxyribonucleic acid 
DN-ARF1 – dominant negative mutant of ARF1 
DN-ARF6 – dominant negative mutant of ARF6 
dsRNA – double stranded ribonucleic acid 
DTT - dithiothreitol 
 
E 
EEA1 – early endosomal antigen 1 
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ECL - enhanced chemiluminescence 
EDTA - ethylenediaminetetraacetic acid 
EFA6 - exchange factor for ARF6 
ELISA - enzyme-linked immunosorbent assay 
 
F 
FC-ARF6 – “fast cycling” ARF6 mutant 
FCS – fetal calf serum 
 
G 
GAP - GTPase-activating protein 
GDP – guanosine diphosphate 
GEF - guanine nucleotide exchange factor 
Git1 - G protein-coupled receptor kinase-interacting protein 1 
Gly - glycine 
GPCR – G-protein coupled receptor 
GPI - glycosylphosphatidylinositol 
GRK - G protein-coupled receptor kinase 
GTP – guanosine triphosphate 
GTP-ARF6 – “GTP locked” ARF6 mutant 
 
H 
HA antigen – hemagglutinin antigen 
HBSS - Hank´s balanced salt solution 
HEK293 cells – Human embryonic kidney 293 cells 
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
 
L 
LPA – lysophosphatidic acid 
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M 
MAP kinase – mitogen activated protein kinase 
MHCI – major histocompatibility complex class I 
MOPr – µ-opioid receptor 
 
N 
NGS – normal goat serum 
NIH – National Institute of Health 
N-myr-ARF6 – N-myristoylated ARF6 peptide 
nPLD2 – catalytically inactive (K758R) PLD2 mutant 
NT - neurotransmitter 
 
P 
PA- phosphatidic acid 
PBS – phosphate buffered saline 
PC – phosphatidyl choline 
PCR – polymerase chain reaction 
PD-ARF6 – PLD-deficient ARF6 mutant 
PH – pleckstrin homology 
PIP2 – phosphatidylinositol-4,5-biphosphate 
PIP5K - phosphatydilinositol-4-phosphate-5-kinase 
PKC - protein kinase C 
PLD2 – phospholipase D2 
PMA - phorbol 12-myristate 13-acetate 
PtdEtOH - phosphatidylethanol 
PTX - pertussis toxin 
PX - phox homology 
 
R 
RIPA buffer - radioimmunoprecipitation buffer 
RISC - RNA-induced silencing complexe 
RNA – ribonucleic acid 
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RNAi – RNA intertference 
 
S 
SDS - sodium dodecyl sulfate 
SDS-PAGE - sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SEM - standard error of the mean 
siRNA - small interfering ribonucleic acid 
 
T 
TAE - Tris-acetate-EDTA 
TEMED - tetramethylethylenediamine 
TfR – transferrin receptor 
TPBS – Tris/phosphate-buffered saline 
 
U 
UV – ultraviolet 
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